Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria by Gogtay, Nithya et al.
Artemisinin-based combination therapy for treating
uncomplicated Plasmodium vivax malaria (Review)
Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2013, Issue 10
http://www.thecochranelibrary.com
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
18ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
21DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
57INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Artemisinin-based combination therapy for treating
uncomplicated Plasmodium vivax malaria
Nithya Gogtay1, Sridharan Kannan2 , Urmila M Thatte2, Piero L Olliaro3, David Sinclair4
1Seth GS Medical College and KEM Hospital, Mumbai, India. 2Department of Clinical Pharmacology, Seth GS Medical College
& KEM Hospital, Mumbai, India. 3UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical
Diseases (TDR), World Health Organization, Geneva, Switzerland. 4Department of Clinical Sciences, Liverpool School of Tropical
Medicine, Liverpool, UK
Contact address: David Sinclair, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool,
L3 5QA, UK. sinclad@liverpool.ac.uk.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 10, 2013.
Review content assessed as up-to-date: 28 March 2013.
Citation: Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Artemisinin-based combination therapy for treating un-
complicated Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD008492. DOI:
10.1002/14651858.CD008492.pub3.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Plasmodium vivax is an important cause of malaria in many parts of Asia and South America, and parasite resistance to the standard
treatment (chloroquine) is now high in some parts of Oceania. This review aims to assess the current treatment options in the light of
increasing chloroquine resistance.
Objectives
To compare artemisinin-based combination therapies (ACTs) with alternative antimalarial regimens for treating acute uncomplicated
P. vivax malaria.
Search methods
We searched the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); MEDLINE; EMBASE; LILACS; and the metaRegister of Controlled Trials (mRCT) up to 28 March 2013 using “vivax” and
“arte* OR dihydroarte*” as search terms.
Selection criteria
Randomized controlled trials comparing ACTs versus standard therapy, or comparing alternative ACTs, in adults and children with
uncomplicated P. vivax malaria.
Data collection and analysis
Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We used recurrent parasitaemia prior
to day 28 as a proxy for effective treatment of the blood stage parasite, and compared drug treatments using risk ratios (RR) and
95% confidence intervals (CIs). We used trials following patients for longer than 28 days to assess the duration of the post-treatment
prophylactic effect of ACTs. We assessed the quality of the evidence using the GRADE approach.
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Main results
We included 14 trials, that enrolled 2592 participants, and were all conducted in Asia and Oceania between 2002 and 2011.
ACTs versus chloroquine
ACTs clear parasites from the peripheral blood quicker than chloroquine monotherapy (parasitaemia after 24 hours of treatment: RR
0.42, 95% CI 0.36 to 0.50, four trials, 1652 participants, high quality evidence).
In settings where chloroquine remains effective, ACTs are as effective as chloroquine at preventing recurrent parasitaemias before day
28 (RR 0.58, 95% CI 0.18 to 1.90, five trials, 1622 participants, high quality evidence). In four of these trials, recurrent parasitaemias
before day 28 were very low following treatment with both chloroquine and ACTs. The fifth trial, from Thailand in 2011, found
increased recurrent parasitaemias following treatment with chloroquine (9%), while they remained low following ACT (2%) (RR 0.25,
95% CI 0.09 to 0.66, one trial, 437 participants).
ACT combinations with long half-lives probably also provide a longer prophylactic effect after treatment, with significantly fewer
recurrent parasitaemias between day 28 and day 42 or day 63 (RR 0.57, 95% CI 0.40 to 0.82, three trials, 1066 participants, moderate
quality evidence). One trial, from Cambodia, Thailand, India and Indonesia, gave additional primaquine to both treatment groups
to reduce the risk of spontaneous relapses. Recurrent parasitaemias after day 28 were lower than seen in the trials that did not give
primaquine, but the ACT still appeared to have an advantage (RR 0.27, 95% CI 0.08 to 0.94, one trial, 376 participants, low quality
evidence).
ACTs versus alternative ACTs
In high transmission settings, dihydroartemisinin-piperaquine is probably superior to artemether-lumefantrine, artesunate plus sulpha-
doxine-pyrimethamine and artesunate plus amodiaquine at preventing recurrent parasitaemias before day 28 (RR 0.20, 95% CI 0.08
to 0.49, three trials, 334 participants, moderate quality evidence).
Dihydroartemisinin-piperaquine may also have an improved post-treatment prophylactic effect lasting for up to six weeks, and this
effect may be present even when primaquine is also given to achieve radical cure (RR 0.21, 95% CI 0.10 to 0.46, two trials, 179
participants, low quality evidence).
The data available from low transmission settings is too limited to reliably assess the relative effectiveness of ACTs.
Authors’ conclusions
ACTs appear at least equivalent to chloroquine at effectively treating the blood stage ofP. vivax infection. Even in areas where chloroquine
remains effective, this finding may allow for simplified protocols for treating all forms of malaria with ACTs. In areas where chloroquine
no longer cures the infection, ACTs offer an effective alternative.
Dihydroartemisinin-piperaquine is themost studiedACT. Itmay provide a longer period of post-treatment prophylaxis than artemether-
lumefantrine or artesunate plus amodiaquine. This effect may be clinically important in high transmission settings whether primaquine
is also given or not.
P L A I N L A N G U A G E S U M M A R Y
Artemisinin-based combination therapy (ACT) for treating non-severe malaria due to Plasmodium vivax
What is P. vivax malaria and how do ACTs work?
P. vivax is one of five species of the malaria parasite known to cause clinical illness. It is a common cause of malaria in Asia, South
America and Oceania. Unlike P. falciparum (the commonest cause of malaria in Africa), P. vivax has a liver stage which is not treated
by most common antimalarial drugs. This liver stage can become active and cause a relapse of clinical illness weeks or even years after
the initial illness.
The standard treatment for vivax malaria has been chloroquine to treat the clinical illness, and a 14-day course of primaquine to clear the
liver stage. In some parts of Oceania the P. vivax parasite in now highly resistant to chloroquine, which makes this treatment ineffective.
Artemisinin-based combination therapies (ACTs) are now the recommended treatment for P. falciparum malaria worldwide. As the
effectiveness of chloroquine for P. vivax declines, alternative therapies are needed. If ACTs are also effective against P. vivax they could
become the standard treatment for all forms of malaria.
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Current ACT combinations do not contain drugs effective against the liver stage of P. vivax so primaquine would still be necessary to
achieve complete cure.
What the research says about the effect of using ACTs
We examined the research published up to 28 March 2013.
Compared to chloroquine
People who are treated with an ACT are probably less likely to have another episode of P. vivax malaria during the next six to eight
weeks than those treated with chloroquine (only dihydroartemisinin-piperaquine, artesunate plus sulphadoxine-pyrimethamine, and
artesunate-pyronaridine have been compared with chloroquine). It is not clear whether this advantage is still present when primaquine
is given to achieve a complete cure.
Compared to alternative ACTs
People who are treated with dihydroartemisinin-piperaquine are probably less likely to have another episode of P. vivaxmalaria during
the next six weeks than those treatedwith alternative ACTs (only artemether-lumefantrine, artesunate plus sulphadoxine-pyrimethamine
and artesunate plus amodiaquine have been compared). This advantage may be present even when additional primaquine is given to
achieve a complete cure.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Artemisinin-based combination therapy compared with chloroquine for uncomplicated P. vivax malaria
Patient or population: Adults and children with uncomplicated P. vivax malaria
Settings: Endemic areas where chloroquine is still an effective treatment for the first 28 days
Intervention: Artemisinin-based combination therapy
Comparison: Chloroquine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Chloroquine ACT
Remaining parasitaemic at
24 hours
52 per 100 22 per 100
(19 to 26)
RR 0.42
(0.36 to 0.50)
1652
(4 studies1)
high2,3,4,5
Remaining febrile after 24
hours
29 per 100 16 per 100
(12 to 20)
RR 0.55
(0.43 to 0.7)
990
(2 studies6)
moderate2,4,5,7
Effective treatment of the
blood stage parasite
As assessed by: Recurrent
parasitaemia before day 28
3 per 100 2 per 100
(1 to 6)
RR 0.58
(0.18 to 1.90)
1622
(5 studies8)
high2,3,4,9
Post-treatment prophylaxis
As assessed by: Recurrent
parasitaemia between day 28
and day 42/56/63
With primaquine RR 0.27
(0.08 to 0.94)
376
(1 study10)
low11,12
6 per 100 2 per 100
(0 to 6)
Without primaquine RR 0.57
(0.40 to 0.82)
1066
(3 studies13)
moderate3,5,14
40 per 100 23 per 100
(16 to 33)
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Serious adverse events 0 per 100 0 per 100
(0 to 2)
RR 1
(0.14 to 7.04)
1775
(5 studies8)
high2,3,4,9
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ACT: artemisinin-based combination therapy
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Awab 2010 AFG (Afghanistan), Kolaczinski 2007 AFG (Afghanistan), Poravuth 2010 ASIA (multi-site), and Phyo 2011 THA (Thailand).
2 No serious study limitations: Awab 2010 AFG , Poravuth 2010 ASIA and Phyo 2011 THA adequately concealed allocation, Kolaczinski
2007 AFG did not, and Krudsood 2007 THA did not adequately describe allocation concealment.
3 No serious inconsistency: The findings of all the trials are consistent.
4 No serious indirectness: The findings of these three studies can reasonably be applied to other settings with similar transmission and
resistance patterns.
5 No serious imprecision: The finding is of a clinically and statistically significant benefit with ACTs.
6 Awab 2010 AFG (Afghanistan) and Poravuth 2010 ASIA (multi-site).
7 Downgraded by 1 for serious inconsistency: The two additional trials (Kolaczinski 2007 AFG; Krudsood 2007 THA) report that fever
clearance was not significantly different between the groups.
8 Awab 2010 AFG (Afghanistan), Kolaczinski 2007 AFG (Afghanistan), Krudsood 2007 THA (Thailand), Poravuth 2010 ASIA (multi-site),
and Phyo 2011 THA (Thailand).
9 No serious imprecision: The finding is of no clinically important difference between ACTs and CQ. Although the 95% CI around the
relative effect is very wide, recurrent parasitaemia before day 28 and serious adverse events were very rare and consequently the 95%
CI around the absolute effect is very narrow.
10 Poravuth 2010 ASIA.
11 Downgraded by 1 for serious indirectness: Poravuth 2010 ASIA delayed primaquine until day 28 and so the course will not have
completed until day 42 the last day of the trial. The effect seen may not be present if primaquine is given in the usual way (on completion
of 3 days of ACT). The period of follow-up is also not long enough to fully assess this effect, the inevitable relapse may simply be
delayed, rather than a reduction in clinical episodes.
12 Downgraded by 1 for serious imprecision: Although statistically significant the 95% CI is wide and includes the possibility of no
appreciable benefit.
13 Awab 2010 AFG continued until day 56, Kolaczinski 2007 AFG to day 42 and Phyo 2011 THA to day 63 (Primaquine was administered
to the participants after day 63).
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14 Downgraded by 1 for serious indirectness: Both studies are from Afghanistan Awab 2010 AFG and Kolaczinski 2007 AFG where
primaquine is not recommended due to a high prevalence of G6PD. The period of follow-up is also not long enough to fully assess this
effect, the inevitable relapse may simply be delayed, rather than a reduction in clinical episodes.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Malaria is a disease of global public health importance whose social
and economic burden is amajor obstacle to humandevelopment in
many of theworlds’ poorest countries (WHO 2012). Transmission
occurs from person to person via the bite of female mosquitoes
infected with the protozoan parasite Plasmodium, of which five
species are capable of causing disease in humans: P. falciparum,P.
vivax, P. malariae, P. ovale, and (rarely)P. knowlesi (WHO 2010).
Although P. falciparum remains the dominant species worldwide,
outside Africa P. vivax is often equally prevalent, and co-infections
in a single clinical episode are also common (Mayxay 2004; Price
2007b). The relative importance of P. vivax has increased over
recent years as control efforts against P. falciparum have shown
signs of success, and as evidence accumulates that P. vivaxmalaria
is not an entirely benign illness (Anstey 2009; Price 2009). P. vivax
accounts for approximately 50%of allmalaria episodes in southern
Asia and theWestern Pacific, and up to 80% in South America and
the eastern Mediterranean region (Mendis 2001; Price 2007b).
Estimates for the total burden of P. vivax are uncertain, ranging
from 72 to 390 million clinical episodes per year (Price 2007b),
but 2.48 billion people are estimated to be living in the areas at
risk of P. vivaxmalaria (Gething 2012).
Resistance of P. vivax to chloroquine, a cheap and simple treat-
ment, is now widespread and has rendered this drug ineffective
in parts of Indonesia and Papua New Guinea (Sumawinata 2003;
Ratcliff 2007a; Karunajeewa 2008; Sutanto 2009). Low levels
of resistance have also been reported from Burma, South Korea,
Vietnam, India, Turkey, Ethiopia, and parts of southern Africa
and South America (Baird 2009; Price 2009; WHO 2010). In
2010, the World Health Organization (WHO) recommended
artemisinin-based combination therapy (ACTs) for treating for
chloroquine-resistant P. vivax malaria (WHO 2012).
Description of the condition
Clinical syndromes
The clinical symptoms of malaria are caused by the direct and
indirect effects of the blood stage parasite (Anstey 2009). Uncom-
plicated malaria is the milder form of the disease which presents as
an acute febrile illness with headache, tiredness, muscle pains, ab-
dominal pains, rigors, sweats, nausea, and vomiting (WHO 2010).
In the absence of adequate treatment, uncomplicated malaria can
progress to severe or fatal forms of the disease characterized by
severe anaemia, respiratory distress, renal failure, thrombocytope-
nia, and coma (Anstey 2009). Such severe disease with P. vivax has
traditionally been considered extremely rare; however, the devel-
opment of more accurate diagnostic tests, particularly polymerase
chain reaction (PCR) techniques capable of reliably excluding P.
falciparum as a cause, have revealed that severe disease due to P. vi-
vaxmay cause significant morbidity (Barcus 2007; Genton 2008;
Tjitra 2008; Baird 2009; Kochar 2009; Price 2009).
A clinical diagnosis of P. vivax malaria can be confirmed by de-
tection and identification of the malaria parasite in the patient’s
blood using light microscopy, by rapid antigen testing kits, or by
PCR techniques (rarely used in a clinical context) (WHO 2010).
The hypnozoite as the cause of spontaneous relapses
P. vivax differs from P. falciparum in having a liver stage, known as
a hypnozoite, which can lie dormant in the liver following an acute
infection.These hypnozoites are not susceptible to the antimalarial
drugs used to treat the acute illness (which act upon the circulating
blood stage parasite), and are the cause of spontaneous relapses
which may occur weeks, months, or even years after the initial
episode (Galappaththy 2007; WHO 2010). The frequency and
timing of these relapses varies geographically, reflecting variations
in the behaviour of locally prevalent strains (Collins 1996; White
2002; Baird 2007). In the tropical regions of southeast Asia and
Oceania the risk of relapse is highest, with the first relapse occur-
ring at around three to five weeks and often recurring repeatedly in
the same patient (Collins 1996; Baird 1997; Baird 2007; Imwong
2007). Relapses in temperate regions are less common, often occur
6 to 12 months later, and usually only once (Galappaththy 2007;
Imwong 2007; Baird 2009).
Radical cure (complete removal of all stages of the malaria parasite
from the infected patient) therefore requires additional therapy
targeted at the hypnozoite. The only drug in common use for this
purpose is primaquine, an 8-aminoquinolone. The current regi-
men recommended by the World Health Organization (WHO)
is 15 mg/kg/day for 14 days, with higher doses necessary is some
parts of southeast Asia and Oceania (Galappaththy 2007; WHO
2010). Of note, primaquine is known to cause haemolysis in peo-
ple with glucose-6-phosphate dehydrogenase (G6PD) deficiency,
a condition that can be frequent in some malaria endemic areas.
These reactions can range from mild and transient to severe and
life-threatening.
Assessing antimalarial efficacy in P. vivax
The hypnozoite causes considerable difficulty in the design and in-
terpretation of P. vivax intervention trials. When P. vivax parasites
reappear in the peripheral blood, which wewill term a ’recurrence’,
there are no reliable methods to distinguish a recrudescence of the
original infection (due to failure to adequately clear the schizont
from the peripheral blood), from a spontaneous relapse (due to
activation of the hypnozoite in the liver) or a re-infection (due to
a new infection acquired from a subsequent mosquito bite) (Baird
2009; WHO 2010).
The most accurate test of a drugs ability to clear the blood stage
would be to measure treatment failure prior to day 16, as post-
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treatment recurrent parasitaemia at this time-point will almost cer-
tainly be due to a recrudescence (Baird 2009; WHO 2010). This
outcome however, may have little ability to discriminate between
drugs, and is too early to exclude the possibility of subsequent re-
crudescence. Trials of ACT in the treatment of P. falciparum have
recorded proven recrudescence well beyond 14 or even 28 days
(Bloland 2003; Sinclair 2009).
Measuring recurrent parasitaemia at time-points later than 16 days
will include failures due to both recrudescences and relapses (
Baird 2009). This distinction is important in understanding the
therapeutic value of a given treatment, though it may be of little
interest to the patient as both may result in a further episodes of
clinical illness.
Demonstration of radical cure requires longer periods of follow-
up, ideally up to one year, but is further complicated by the pos-
sibility that the observed recurrence is not due to recrudescence
or relapse but to re-infections (White 2002; WHO 2010). The
follow-up period needed to make conclusions on radical cure,
rather than delayed relapse, must exceed both the individual drug
clearance time (the time taken to effectively reduce the drug lev-
els to undetectable), and the expected relapse time of local strains
(Bloland 2003; Baird 2009).
Drug resistance
Chloroquine resistance is a major problem, and there is further
evidence of resistance developing among P. vivax strains to sulpha-
doxine-pyrimethamine (a common second-line treatment), and
of decreased primaquine efficacy in parts of southeast Asia (Baird
2009).
A 28-day test has been devised to assess chloroquine resistance
in vivo. This defines resistance as the recurrence of P. vivax par-
asitaemia before day 28 in the presence of adequate chloroquine
drug levels, regardless of the nature of the recurrence (recrudes-
cence, relapse, or re-infection). Prior to the development of resis-
tance, recurrent P. vivax parasitaemia following chloroquine treat-
ment was rarely seen before 28 days (Baird 1997; Baird 2009). It
seems reasonable therefore to expect a replacement drug to also
prevent recurrence (of any cause) for at least 28 days.
To combat the growing problem of resistance among P. falci-
parum strains, theWHOhas now recommended thatP. falciparum
malaria is always treated using a combination of two drugs which
act at different biochemical sites within the parasite. Parasites car-
rying a mutation producing resistance arising spontaneously dur-
ing treatment, should then be killed by the partner drug, reducing
or delaying the development of resistance and increasing the useful
lifetime of each individual drug (White 1996;White 1999;WHO
2010). The availability of effective (and cheap) monotherapies for
P. vivax, has until now negated the need for a similar approach
with P. vivax. However, there are several reasons why ACT treat-
ment for both species might now be desirable:
• both parasites are co-endemic is parts of the world, and
individuals can be infected with both species;
• many malaria episodes continue to be diagnosed clinically
without identification of the species;
• it would simplify national treatment protocols, and provide
a rational approach to both proven, and undetected, P.
falciparum and P. vivax co-infections;
• it may decrease the market availability of monotherapies,
and aid in the combat of drug-resistance.
Description of the intervention
Artemisinin and its derivatives (artesunate, artemether, and di-
hydroartemisinin) are short-acting antimalarial drugs which have
been shown to produce rapid relief from clinical symptoms
and rapid clearance of the parasite from the peripheral blood
(Pukrittayakamee 2000;WHO2010). They are usually combined
with a longer-acting partner drug to produce ACTs. Until recently
there was no known resistance to the artemisinin derivatives but
some resistance amongP. falciparum species has nowbeen reported
in southeast Asia and is being investigated (Dondorp 2009).
Artemisinin derivatives are generally reported as being well-toler-
ated, and the safety profile of ACTs may be largely determined by
the partner drug (Taylor 2004). Studies of artemisinin derivatives
in animals have reported significant neurotoxicity (brain damage),
but this has not been seen in human studies (Price 1999). Animal
studies have also shown adverse effects on the early development
of the foetus, but the artemisinin derivatives have not been fully
evaluated during early pregnancy in humans. Other reported ad-
verse events include gastrointestinal disturbance (stomach upset),
dizziness, tinnitus (ringing in the ears), neutropenia (low levels
of white blood cells), elevated liver enzymes (a marker for liver
damage), and electrocardiographic (ECG) abnormalities (changes
in cardiac conduction). Most studies, however, have found no ev-
idence of ECG changes, and only non-significant changes in liver
enzymes (Nosten 2007; WHO 2010). The incidence of type 1
hypersensitivity (allergic) reactions is reported to be approximately
1 in 3000 patients (Nosten 2007).
How the intervention might work
Therapy for P. vivax is divided into two components. First, there is
removal of the blood stage of the parasite by a drug with schizonti-
cidal activity, traditionally chloroquine. Second, there is treatment
of the liver stage using a hypnozonticidal drug, usually primaquine,
to achieve a radical cure. The artemisinin derivatives do not have a
substantial effect on the liver stage of the parasite and therefore the
primary aim of ACT treatment is eradication of the blood stage
parasite, and relief of clinical symptoms (Pukrittayakamee 2000;
WHO 2010).
In areas of high transmission where the risk of new infections is
high, the risks associated with primaquine, particularly the risk of
haemolysis in patients with G6PD deficiency, may outweigh the
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clinical benefits (WHO 2010). In this scenario, where primaquine
is not routinely given, treatments which delay or prevent the initial
relapses could have public health benefits such as; reduced clinical
episodes, reduced loss of work, and reduction inmalaria-associated
anaemia.
A secondary aim of ACT treatment therefore might be to delay
clinical relapse, and there are now several trials which have investi-
gated this (Hasugian 2007; Ratcliff 2007b). However, the ability
of an ACT to delay the first relapse is critically dependent on the
half-life of the partner drug, with long half-life drugs still being
present (in sufficient concentration) at the time of the first spon-
taneous relapse to clear the resultant blood stage parasites and pre-
vent a recurrent clinical illness. This may be a desirable property
in a drug combination from a patient perspective, but could con-
tribute to further resistance developing as the partner drug is left
unprotected by the rapidly eliminated artemisinin derivative.
Alternatively an ACT co-administered with the recommended 14
days of primaquine could demonstrate superiority to monothera-
pies plus primaquine if the ACT had fewer recrudescent failures,
if it prevented re-infections (as a function of its long half-life), or
if it delayed relapses due to primaquine failure.
In addition, the artemisinin derivatives have been shown to have
an effect on developing Plasmodium gametocytes, which are the
stage of the parasite capable of infecting mosquitoes and therefore
an important stage in the transmission cycle (Price 1996). The
interpretation of this indirect measure for reduced transmission is
however unclear; there is evidence that even submicroscopic (un-
detectable) gametocytes are capable of transmission, and there is
no consensus on what might constitute a clinically relevant reduc-
tion (Targett 2001). We have included it as an outcome here for
completeness.
Why it is important to do this review
ACTs are now the recommended therapy for P. falciparummalaria
worldwide and despite the initial financial and programmatic hur-
dles they are now being used in the majority of malaria endemic
countries (WHO 2010).
This review seeks to assess the comparative effectiveness of ACTs
for treating P. vivax malaria.
O B J E C T I V E S
To compare ACTs with alternative antimalarial regimens for treat-
ing acute, uncomplicated P. vivax malaria and the prevention of
relapses.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
Adults and children (including pregnant or lactating women and
infants) with symptomatic, microscopically confirmed, uncompli-
cated P. vivax malaria.
In studies recruiting patients with P. falciparum and P. vivaxmono-
or co-infections, only the data from patients with proven P. vivax
(+/- P. falciparum) at baseline were included.
Types of interventions
Intervention
• A 3-day course of an ACT.
Control
• A recognized non-ACT antimalarial therapy (chloroquine,
sulphadoxine-pyrimethamine, amodiaquine, mefloquine,
quinine, or combinations).
Or:
• A 3-day course of an alternative ACT.
Types of outcome measures
Primary outcomes
• Recurrence of P. vivax parasitaemia by days 14 and 28.
(The term recurrence simply refers to reappearance of P. vivax
parasites in the peripheral blood. It may include recrudescences,
relapses, and re-infections).
Secondary outcomes
• Parasite clearance: the proportion of patients clear of
parasites on each day, or the mean or median time to first
negative blood smear.
• Fever clearance: the proportion of patients afebrile on each
day, or the mean or median time to becoming afebrile.
• Recurrence of P. vivax parasitaemia at one to 12 months.
• Haematological recovery: changes in haemoglobin from
baseline to last day of follow-up.
• Measures of gametocyte carriage.
• Serious adverse events that require patients to stop
treatment or be admitted to hospital.
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Search methods for identification of studies
All relevant studies regardless of language or publication status
were considered (published, unpublished, in press, or ongoing).
Electronic searches
We conducted a search of the following databases up to 28 March
2013: Cochrane Infectious Disease Group Specialized Register;
Cochrane Central Register of Controlled Trials (CENTRAL),
published in The Cochrane Library; MEDLINE; EMBASE; and
LILACS, using the search terms we have detailed in Table 1. We
also searched themetaRegister of Controlled Trials (mRCT) using
“vivax” and “arte* OR dihydroarte*” as search terms.
Searching other resources
Wereviewed the reference lists of all trials identified by themethods
described above for any further trials, and contacted individual
researchers working in the field.
Data collection and analysis
Selection of studies
David Sinclair (DS) and Kannan Sridharan (KS) independently
reviewed the results of the literature search and obtained full text
copies of all trials thought relevant to this review.
DS, KS, and Urmila Thatte (UT) then independently assessed
the eligibility of each trial for inclusion in this review using an
eligibility form based on the inclusion criteria stated above, and
reported the reasons for their exclusion in the ’Characteristics
of excluded studies’ table. Disagreements were resolved through
discussion.
Data extraction and management
Two authors (Nithya Gogtay (NG), DS, and KS) independently
extracted data using a pre-tested data extraction form, and ex-
tracted data on trial characteristics including: trial site, year, lo-
cal malaria prevalence and transmission, trial methods, partici-
pants, interventions, and outcomes. Disagreements were resolved
through discussion and review of the trial report.
For each outcome we extracted the number randomized and the
number analysed in each treatment group, and calculated and
reported the loss to follow-up in each group.
For dichotomous outcomes we extracted the number of partic-
ipants experiencing the event, and for continuous outcomes we
extracted the arithmetic means and standard deviations for each
treatment group.
We analysed the data using Review Manager 5.
Assessment of risk of bias in included studies
Two authors (NG and KS) independently assessed the method-
ological quality of each trial, using The Cochrane Collaboration’s
tool for assessing the risk of bias (ReviewManager 5).We followed
the guidance to assess whether trials took adequate steps to reduce
the risk of bias across six domains: sequence generation, allocation
concealment, blinding (of participants, personnel, and outcome
assessors), incomplete outcome data, selective outcome reporting,
and other sources of bias. We categorized our judgements as ’yes’
(low risk of bias), ’no’ (high risk of bias), or ’unclear’. Where a trial
was at unclear risk of bias, we attempted to contact the authors
for clarification.
Measures of treatment effect
Dichotomous data are combined using risk ratios and continuous
data using mean differences. Both measures are presented with
95% confidence intervals (CIs). Medians and ranges are only re-
ported in tables.
Dealing with missing data
The primary analysis is a complete-case analysis. We excluded
participants who were lost to follow-up or who developed P. fal-
ciparum parasitaemia during follow-up, and conducted a sensi-
tivity analyses as described below to evaluate the robustness of
this methodology. Participants who developedmixed parasitaemia
during follow-up were treated as failure in the same way as recur-
rence of P. vivax mono-infections.
If data from the trial reports were insufficient, unclear, or missing,
we attempted to contact the authors for additional information.
Assessment of heterogeneity
We assessed heterogeneity amongst trials by inspecting the forest
plots (to detect overlapping CIs), the I² statistic with a level of
50% to denote moderate levels of heterogeneity, and applying the
Chi2 test with a P value of 0.10 to indicate statistical significance.
Assessment of reporting biases
There were too few included trials to assess publication bias.
Data synthesis
We analysed the data using Review Manager 5, and compared
treatments directly using pair-wise meta-analyses. We stratified by
time-point, and for some analyses, further stratified the results by
transmission intensity and known presence of resistance.
When pooling data from comparisons including different combi-
nations (such as any ACT versus chloroquine) we used the ran-
dom-effects model as we were looking for an ’average’ effect rather
than one true underlying effect. Where pooling only within a sin-
gle comparison we used the fixed-effect model when there was
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no statistically significant heterogeneity, and the random-effects
model when there was moderate heterogeneity. Where a pooled
meta-analysis was considered to be meaningless because of clinical
or substantial heterogeneity the results were presented in a forest
plot without a pooled estimate of effect.
Subgroup analysis and investigation of heterogeneity
The small number of included trials precluded subgroup analysis.
Sensitivity analysis
We conducted four sensitivity analyses to restore the integrity of
the randomization process and test the robustness of our results.
• Sensitivity analysis 1: P. falciparum cases added in as failures.
• Sensitivity analysis 2: All exclusions added in as failures.
• Sensitivity analysis 3: P. falciparum cases added in as
successes.
• Sensitivity analysis 4: All exclusions added in as successes.
R E S U L T S
Description of studies
Results of the search
The search was conducted in December 2008 and repeated in
November 2009, March 2011 and up to 28 March 2013. In total
65 trials were identified as being potentially relevant to this review,
of which 27 were excluded on abstract screening. Thirty-eight full
text articles were assessed for eligibility of which 14 are included,
21 are excludedwith reasons, and three await classificationpending
further information from the trial authors (in two studies it is
unclear whether any participants had P. vivax infection at baseline
(van Vugt 2002; Janssens 2007), and in one only a conference
abstract is available (Shin 2011). See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Fourteen studies are included, all conducted in Asia and Ocea-
nia between 2002 and 2011; five from Thailand (Ashley 2004
THA; Ashley 2005 THA; Hutagalung 2005 THA; Krudsood
2007 THA; Phyo 2011 THA), three from Indonesia (Hasugian
2007 IDN; Ratcliff 2007 IDN; Sutanto 2013 IDN), two from
Myanmar (Smithuis 2006 MMR; Smithuis 2010 MMR), two
from Afghanistan (Kolaczinski 2007 AFG; Awab 2010 AFG), one
from Papua New Guinea (Karunajeewa 2008 PNG), and one
multicentre trial from Cambodia, Thailand, India, and Indonesia
(Poravuth 2010 ASIA). (We have added a country code to the
study ID to aid interpretation).
The trial sites in Indonesia and Papua New Guinea are described
as having high transmission and high levels of chloroquine resis-
tance amongstP. vivax species (Hasugian 2007 IDN;Ratcliff 2007
IDN; Karunajeewa 2008 PNG). The studies sites in Thailand,
Myanmar and Afghanistan are described as having low transmis-
sion. Chloroquine resistance amongst P. vivax is also likely to be
low in these settings but not all trial authors stated this specifi-
cally. The multicentre trial (Poravuth 2010 ASIA) is likely to have
included sites with variable levels of transmission and resistance.
The 14 studies included a total of 2636 participants. Of these,
67.5% were diagnosed with P. vivax mono-infection at baseline,
9.7% had co-infections with P. vivax and P. falciparum, and for
22.8% it was unclear how many had mixed infections. Only five
studies co-administered primaquine at the recommended dose to
clear the liver stage of the parasite (Hasugian2007 IDN;Krudsood
2007 THA; Ratcliff 2007 IDN; Poravuth 2010 ASIA; Sutanto
2013 IDN).
One trial followed participants for 28 days after enrolment
(Krudsood 2007 THA). This period is informative on the ability
of the ACT to clear the blood stage of P. vivax but is not long
enough to adequately assess recurrent parasitaemias due to spon-
taneous relapses or re-infections. Seven studies conducted a 42
day follow-up (Hutagalung 2005 THA; Smithuis 2006 MMR;
Hasugian 2007 IDN; Kolaczinski 2007 AFG; Ratcliff 2007 IDN;
Karunajeewa 2008 PNG; Poravuth 2010 ASIA), one continued
until day 56 (Awab 2010 AFG), and four continued until day 63
(Ashley 2004 THA; Ashley 2005 THA; Smithuis 2010 MMR;
Phyo 2011 THA). One trial continued an extended follow-up for
one year (Sutanto 2013 IDN).
Further characteristics of the included studies are in the ’
Characteristics of included studies’ table.
Excluded studies
The studies and reasons for their exclusion are given in the
’Characteristics of excluded studies’ table.
Risk of bias in included studies
The risk of bias assessments are summarised in Figure 2, and
the reasons for these judgements given in the ’Characteristics of
included studies’ tables.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Eleven studies adequately concealed allocation to be considered
at low risk of bias. In two studies the description was not clear
enough to make a judgement (Hutagalung 2005 THA; Krudsood
2007 THA) and one trial did not conceal allocation (Kolaczinski
2007 AFG).
Blinding
Ten studies adequately blinded the outcome assessors (the labo-
ratory staff ) to be at low risk of bias for the primary outcome.
In four studies it was unclear whether this was done (Hutagalung
2005 THA; Smithuis 2006MMR; Krudsood 2007 THA; Sutanto
2013 IDN).
Incomplete outcome data
Five studies had high levels of attrition which could have
introduced some bias into their results (Ashley 2004 THA;
Hasugian 2007 IDN; Krudsood 2007 THA; Ratcliff 2007 IDN;
Karunajeewa 2008 PNG).
Selective reporting
We found no evidence of selective reporting.
Other potential sources of bias
Wehave incorporated data fromfive trials whichwere primarily fo-
cused on the treatment of P. falciparum (Ashley 2004 THA; Ashley
2005 THA; Hutagalung 2005 THA; Smithuis 2006 MMR;
Smithuis 2010 MMR). From these trials we have included only
the very small subgroups of patients who had mixed P. falciparum
and P. vivax at baseline. As such, these samples cannot be consid-
ered to be truly randomized, and prognostic balance is unlikely to
have been achieved due to the low sample size.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: ACT versus CQ; Summary of findings 2 Summary
of findings: DHA-P versus alternative ACTs in high transmission
settings with known CQ resistance
Comparison 1. ACT versus chloroquine monotherapy
Four trials compared WHO recommended ACTs with
chloroquinemonotherapy (CQ); dihydroartemisinin-piperaquine
(DHA-P) (Awab 2010 AFG; Phyo 2011 THA), artesunate plus
sulphadoxine-pyrimethamine (AS+SP) (Kolaczinski 2007 AFG),
and artemether-lumefantrine (AL6) (Krudsood 2007 THA).
One additional multicentre trial (with study sites in Cambo-
dia, Thailand, India, and Indonesia), compared a new combina-
tion; artesunate-pyronaridine (AS-Py)with chloroquine (Poravuth
2010 ASIA). This combination is not yet recommended by the
WHO.
Early clinical response to treatment
ACTs appear to consistently clear parasites faster than chloroquine
(relative risk of remaining parasitaemic on Day 1: RR 0.42, 95%
CI 0.36 to 0.50; Day 2: RR 0.18, 95%CI 0.05 to 0.74; Day 3: RR
0.08, 95% CI 0.01 to 0.43, four trials, 1652 participants, Analysis
1.1). In addition, two trials report a statistically significant reduc-
tion in median parasite clearance time with an ACT (Krudsood
2007 THA; Poravuth 2010 ASIA; see Table 2).
ACTs also appear to clear fever faster than chloroquine, with a
lower risk of remaining febrile with ACT at the end of day 1 and
day 2 (relative risk of remaining febrile on Day 1: RR 0.55, 95%
CI 0.43 to 0.70, two trials, 990 participants; Day 2: RR 0.53,
95% CI 0.31 to 0.91, three trials, 1390 participants, Analysis
1.2). In addition, Krudsood 2007 THA found a trend towards a
reduced mean fever clearance time with AL6 although this did not
reach statistical significance (see Table 3). Kolaczinski 2007 AFG
reported no significant difference in fever clearance times between
AS+SP and CQ but only presented the data graphically.
Recurrent parasitaemia before day 28
Overall, ACTs have not been shown to reduce recurrent para-
sitaemias before day 28 compared to chloroquine (RR 0.58, 95%
CI 0.18 to 1.90, five trials, 1622 participants, Analysis 1.3).
However, in four of these trials resistance to chloroquine appeared
to be very low with very few recurrent parasitaemias before day
28 (Analysis 1.3). In this scenario, the four ACTs tested (DHA-P,
AS+SP, AL6 and AS-Py) were at least as effective as chloroquine
at treating the initial infection.
In the fifth trial (conducted in Thailand), DHA-P reduced re-
current parasitaemias compared to chloroquine (RR 0.25, 95%
CI 0.09 to 0.66, one trial, 437 participants, (Analysis 1.3). This
benefit appears to be due to an increased failure rate with CQ in
this study setting (9% of participants had recurrent parasitaemias
before day 28 following CQ).
Recurrent parasitaemia after day 28
Four trials followed up beyond day 28, but only one trial gave
additional primaquine to achieve radical cure (Poravuth 2010
ASIA).
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Compared toCQ, Poravuth 2010 ASIA found that AS-Py reduced
the risk of recurrent parasitaemia between Day 28 and 42 (RR
0.27, 95% CI 0.08 to 0.94, one trial, 376 participants, Analysis
1.3). The primaquine given in this trial was delayed until Day 28
and so the course will not have been completed until Day 42.
In the absence of primaquine, recurrent parasitaemias after day
28 were more common, but AS+SP, AL6, and DHA-P were still
shown to have an advantage over CQ (RR 0.57, 95% CI 0.40
to 0.82, three trials, 1066 participants, Analysis 1.3). The longest
follow-up was 63 days in a trial evaluating DHA-P (Phyo 2011
THA). In this trial, 55% of participants experienced recurrent
parasitaemia after day 28 following treatment with DHA-P, com-
pared to 80% following CQ.
Secondary outcomes
Only one trial (Kolaczinski 2007 AFG) reported on gametocyte
clearance. ByDay 3, only one patient had gametocytes still present
on a blood film, although gametocytes were cleared quicker in the
group treated with AS+SP (one trial, 190 participants, Analysis
1.4).
Kolaczinski 2007 AFG also reported the mean packed cell volume
on day 28 (a measure of anaemia) as not significantly different
between groups.
Severe adverse events were rare in these trials and no difference has
been shown (five trials, 1775 participants, Analysis 1.5).
Comparison 2. ACT versus chloroquine plus
sulphadoxine-pyrimethamine
One four-arm trial from Papua New Guinea (Karunajeewa 2008
PNG), compared three ACTs (DHA-P, AL6, AS+SP) with a
CQ+SP combination. P. vivax transmission in this region is de-
scribed as high, and chloroquine resistance among P. vivax strains
has been rising since the late 1980s.
Early response to treatment
In this trial all three ACTs cleared parasites faster than CQ+SP
(relative risk of remaining parasitaemic on Day 1: RR 0.22, 95%
CI 0.15 to 0.34; Day 2: RR 0.09, 95%CI 0.03 to 0.27; Day 3: RR
0.17, 95 %CI 0.03 to 0.81, one trial, 195 participants, Analysis
2.1), but there was no significant difference in fever clearance (one
trial, 195 participants, Analysis 2.2).
Recurrent parasitaemia before day 28
The high recurrence rate during the first 28 days after treatment
with CQ+SP confirms the presence of high levels of CQ and SP
resistance at this trial site. Only DHA-P was significantly better
than CQ+SP but the trial is underpowered to rule out superiority
of AL6 or AS+SP (DHA-P versus CQ+SP; RR 0.35, 95% CI
0.16 to 0.77, one trial, 96 participants, Analysis 2.3). Of note,
recurrences occurred within 14 days of treatment with all three
ACTs, suggesting failure to clear the initial blood stage, and at day
28 the number of recurrences was 15% even with DHA-P (the
best performing ACT).
Recurrent parasitaemia after day 28
DHA-P remained superior to CQ+SP during the period 28 to 42
days (RR 0.26, 95% CI 0.09 to 0.69, one trial, 53 participants,
Analysis 2.3), but 27.8% of participants treated with DHA-P who
completed 42 days follow-up experienced a recurrence. The dif-
ferences between AL6, AS+SP and CQ+SP remained non-signifi-
cant. The trial did not give primaquine to achieve radical cure.
Secondary outcomes
This trial did not report on P. vivax gametocytaemia. Trial authors
did not report any serious adverse events.
Comparison 3. ACT versus quinine
One trial, in Indonesian soldiers diagnosed with P. vivax para-
sitaemia when returning from an endemic area, compared DHA-
P against quinine (Sutanto 2013 IDN). Primaquine was offered to
patients in the quinine group for 14 days fromday 0, while patients
in the DHA-P group commenced primaquine for 14 days from
day 28. The trial participants were followed up for 12 months and
all recurrences were presumed to be relapses as the area was free of
endemic malaria.
Early response to treatment
All but three participants were clear of parasites by day three (two
in the DHA-P group and one in the quinine group), with no
significant difference between groups (one trial, 72 participants,
Analysis 3.1). Trial authors did not report fever clearance.
Recurrent parasitaemia before day 28
None of the trial participants had a recurrence of parasitaemia
before day 28 (one trial, 72 participants, Analysis 3.2).
Recurrent parasitaemia after day 28
Seven participants in the quinine + primaquine arm had recurrent
parasitaemia between days 36 and 194, compared to two with
DHA-P (one at day 82 and the second at day 126). The difference
was not statistically significant (one trial, 72 participants, Analysis
3.2).
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Secondary outcomes
This trial did not report P. vivax gametocytaemia.
Trial authors reported four serious adverse events (appendicitis,
colitis, and two trauma), but they did not consider any to be related
to the medication.
Comparison 4. ACT versus an alternative ACT
Eight studies directly compared ACTs in the treatment of P. vivax.
Five studies are from low transmission settings andmainly focused
on the treatment of P. falciparum (Ashley 2004 THA; Ashley 2005
THA; Hutagalung 2005 THA; Smithuis 2006 MMR; Smithuis
2010 MMR). We present unpublished data for only those partic-
ipants who had a P. vivax co-infection at baseline. The numbers
included are very small and should be interpreted with caution.
The three studies from high transmission areas also included par-
ticipants with P. vivax mono-infection (Hasugian 2007 IDN;
Ratcliff 2007 IDN; Karunajeewa 2008 PNG).
Early clinical response to treatment
There is no evidence that any one ACT clears parasites or fever
faster than another (five trials, 278 participants, Analysis 4.1; Anal-
ysis 4.2; Analysis 4.3; Analysis 4.4).
An additional two trials comment that 99% of all participants
treated with ACTs were afebrile after 48 hours (Hasugian 2007
IDN; Ratcliff 2007 IDN).
Recurrent parasitaemia before day 28
DHA-P versus AS+MQ
Recurrent parasitaemia before day 28 was rare with both these
ACTs in the small subgroups of participants with P. vivax co-in-
fections, from trials in Thailand andMyanmar, and no statistically
significant difference was apparent (four trials, 186 participants,
Analysis 4.5).
DHA-P versus AL6
Treatment with DHA-P was superior to AL6, resulting in fewer
recurrent parasitaemias before day 28 in three small trials from
Papua New Guinea, Indonesia, and Myanmar (RR 0.15, 95% CI
0.04 to 0.58, three trials, 237 participants, Analysis 4.5)
DHA-P versus AS+AQ
Treatment with DHA-P was superior to AS+AQ; resulting in sig-
nificantly fewer recurrent parasitaemias before day 28 in one small
trial from Indonesia (RR 0.04, 95% CI 0.00 to 0.73, one trial, 85
participants, Analysis 4.5).
DHA-P versus AS+SP
Treatment with DHA-P was superior to AS+SP; resulting in sig-
nificantly fewer recurrent parasitaemias before day 28 in one trial
from Papua New Guinea (RR 0.32, 95% CI 0.15 to 0.72, one
trial, 77 participants, Analysis 4.5)
AS+MQ versus AL6
In two trials with small subgroups of patients with P. vivax co-
infections, those treated with AS+MQ had fewer recurrent para-
sitaemias before day 28 than those treated with AL6 (RR 0.06,
95% CI 0.01 to 0.40, two trials, 56 participants, Analysis 4.5).
Other comparisons
No other significant differences have been shown but only very
limited data are available.
Recurrent parasitaemia after day 28
DHA-P versus AS+MQ
No difference has been shown between DHA-P and AS+MQ in
preventing recurrent parasitaemias after Day 28 (four trials, 169
participants, Analysis 4.6). All of the data presented represent small
subgroups of patients recruited into trials of ACTs in the treatment
of P. falciparum who were found to have co-infections at baseline.
DHA-P versus AL6
In a high transmission setting in Indonesia, Ratcliff 2007 IDN
found treatment with DHA-P to result in significantly fewer re-
current parasitaemias between Day 28 and 42 (RR 0.18, 95% CI
0.07 to 0.50, one trial, 106 participants, Analysis 4.6). The pri-
maquine given in this trial was delayed until Day 28 and so the
course will not have been completed until Day 42.
In Papua New Guinea Karunajeewa 2008 PNG did not give pri-
maquine, and found no statistically significant difference in re-
current parasitaemias between Day 28 and 42 (one trial, 46 par-
ticipants, Analysis 4.6). There were however significantly fewer
recurrent parasitaemias over the full 42 day period (Analysis 4.7).
DHA-P versus AS+AQ
Hasugian 2007 IDN offered an unsupervised course of pri-
maquine to all participants on completion of their ACT regimen
in this trial from a high transmission setting in Indonesia. Despite
this, treatment with DHA-P still resulted in significantly fewer
recurrent parasitaemias between Day 28 and 42 (RR 0.26, 95%
CI 0.08 to 0.88, one trial, 73 participants, Analysis 4.6).
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Other comparisons
In Papua New Guinea Karunajeewa 2008 PNG did not show
a significant difference between DHA-P and AS+SP (one trial,
50 participants, Analysis 4.6), or AL6 and AS+SP (one trial, 38
participants, Analysis 4.6).
The remaining data are very limited and underpowered to detect
differences.
Secondary outcomes
All of these trials included participants with P. falciparum mono-
infection and secondary outcomes were unavailable for just the
participants who had a P. vivax mono- or co-infection. We were
given access to the data sets from three of the trials, however the
numbers of participants were too low to meaningfully compare
secondary measures.
Comparison 5. DHA-P versus alternative ACTs
Of the eight studieswhich directly comparedACTs, seven included
a treatment arm which received DHA-P. It is therefore the most
studied ACT for the treatment of P. vivax.
We have summarized the relative effects of DHA-P in two addi-
tional forest plots. We have stratified this analysis by the level of
P. vivax transmission, as reported by the trial authors. This anal-
ysis was pre-planned as transmission intensity influences the risk
of a patient experiencing a new infection, an important factor in
assessing post-treatment prophylaxis.
In low transmission settings
The data from low transmission settings are all from small sub-
groups of patients in trials whose primary objective was to inves-
tigate ACTs in the treatment of P. falciparum. There is a trend
towards benefit with DHA-P but this is not statistically significant
and is at high risk of bias due to the very small sample sizes (Anal-
ysis 5.1).
In high transmission settings
In high transmission settings DHA-P appears superior to alter-
native ACTs (AL6, AS+AQ, and AS+SP) at preventing recurrent
parasitaemia before Day 28 (RR 0.20, 95% CI 0.08 to 0.49, three
trials, 344 participants, Analysis 5.2). It also appears superior at
preventing recurrences between days 28 and 42 although this was
only statistically significant in the two trials from Indonesia (RR
0.21, 95% CI 0.10 to 0.46, two trials, 179 participants, Analysis
5.2). Due to the way these two trials administered primaquine,
some doubt remains about whether this effect is present when an
adequate course of primaquine is given; Ratcliff 2007 IDN de-
layed the course of primaquine until Day 28 so the course will not
have been completed until the last day of the trial, and Hasugian
2007 IDN ’offered an unsupervised course of primaquine to all
participants on completion of their ACT’.
Sensitivity analysis
We conducted a series of sensitivity analyses, as described in the
methods section, to restore the integrity of the randomization
process and evaluate the robustness of our results. These changes
did not have a significant impact on the results.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Dihydroartemisinin-piperaquine compared with alternative artemisinin-based combination treatments for uncomplicated P. vivax malaria
Patient or population: Adults and children with uncomplicated P. vivax malaria
Settings: Settings with high transmission of P. vivax (chloroquine resistance is also reported as high)
Intervention: Dihydroartemisinin-piperaquine
Comparison: Alternative ACTs
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Alternative ACT DHA-P
Effective treatment of the
blood stage parasite
As assessed by: Recurrent
parasitaemia before day 28
35 per 100 7 per 100
(3 to 17)
RR 0.20
(0.08 to 0.49)
334
(3 studies1,2)
moderate3,4,5,6
Post-treatment prophylaxis
As assessed by: Recurrent
parasitaemia between day 28
and 42
With primaquine RR 0.21
(0.1 to 0.46)
179
(2 studies2)
low6,7,8,9
34 per 100 7 per 100
(3 to 16)
Without primaquine RR 0.40
(0.14 to 1.10)
66
(1 study1)
very low10,11,12
33 per 100 13 per 100
(5 to 37)
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; DHA-P: dihydroartemisinin-piperaquine; ACT: Artemisinin-based combination therapy
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Karunajeewa 2008 PNG (Papua New Guinea).
2 Hasugian 2007 IDN and Ratcliff 2007 IDN (Indonesia).
3 No serious risk of bias: Allocation was adequately concealed in these studies to be considered at low risk of bias.
4 Downgraded by 1 for serious inconsistency: There was some clinical heterogeneity between trials. DHA-P did not perform as well in
Papua New Guinea as it has elsewhere, however it was still superior to AL6 and AS+SP.
5 No serious indirectness: Studies include adults and children and were conducted in areas where transmission is high and chloroquine
resistance is well documented.
6 No serious imprecision: Both limits of the 95% CI suggest an appreciable clinical benefit with DHA-P.
7 Downgraded by 1 for serious risk of bias: Losses to follow-up were high (>20% at this time-point).
8 No serious inconsistency: Statistical heterogeneity was low.
9 Downgraded by 1 for serious indirectness: Ratcliff 2007 IDN delayed the administration of Primaquine until day 28 and so the course
will not have been completed until the last day of the trial. Hasugian 2007 IDN offered unsupervised primaquine to all participants on
completion of their ACT, this reflects normal practice but it is not clear how many participants completed their course. The period of
follow-up is also not long enough to fully assess this effect, the inevitable relapse may simply be delayed, rather than a reduction in
clinical episodes.
10 Downgraded by 1 for serious risk of bias: Losses to follow-up were high (>20% at this time-point).
11 Downgraded by 1 for serious indirectness: Only one study has assessed this outcome. Recurrent parasitaemia was higher with all
three ACTs than seen elsewhere. This trial is therefore not easily extrapolated to other sites.
12 Downgraded by 1 for serious imprecision: The 95% CI of the effect estimate is wide and includes an important clinical benefit and no
difference between the treatments.
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D I S C U S S I O N
Summary of main results
ACTs versus chloroquine
ACTs clear parasites from the peripheral blood quicker than
chloroquine monotherapy (high quality evidence).
In settings where chloroquine remains effective, ACTs are as ef-
fective as chloroquine at preventing recurrent parasitaemias before
day 28 (high quality evidence). In four of these trials, recurrent
parasitaemias before day 28 were very low following treatment
with both chloroquine and ACTs. The fifth trial, from Thailand
in 2011, found increased recurrent parasitaemias following treat-
ment with chloroquine (9%), while they remained low following
ACT (2%).
ACT combinations with long half-lives probably also provide a
longer prophylactic effect after treatment, with significantly fewer
recurrent parasitaemias between day 28 and day 42 or day 63
(moderate quality evidence). One trial, from Cambodia, Thailand,
India, and Indonesia, gave additional primaquine to both treat-
ment groups to reduce the risk of spontaneous relapses. Recurrent
parasitaemias after day 28 were lower than seen in the trials not
giving primaquine, but the ACT still appeared to have an advan-
tage (low quality evidence).
ACTs versus alternative ACTs
No individual ACT has been shown to clear parasites or fever
quicker than an alternative.
Dihydroartemisinin-piperaquine is the most studied ACT, and in
high transmission settings it is probably superior to artemether-
lumefantrine, artesunate plus sulphadoxine-pyrimethamine, and
artesunate plus amodiaquine at preventing recurrent parasitaemias
before day 28 (moderate quality evidence).
Dihydroartemisinin-piperaquine may also have an improved post-
treatment prophylactic effect lasting for up to six weeks, and this
effectmay be present evenwhenprimaquine is also given to achieve
radical cure (low quality evidence).
The data available from low transmission settings is too limited to
reliably assess the relative effectiveness of ACTs.
Overall completeness and applicability of
evidence
The included trials were from a variety of settings in Asia and
included both adults and children with uncomplicated P. vivax
malaria. The findings can therefore be reasonably applied to areas
within Asia, but we advise caution in extrapolation to other re-
gions. Of note, there are no trials from South America.
The epidemiology of P. vivax is such that interpretation of the
results is difficult. In this review we have taken parasitaemia before
day 28 as a proxy for failure to clear the blood stage parasite. This
is not entirely correct and this outcome may include some early
relapses. When drugs with long half-lives are used this may also
exclude some true recrudescences which occur beyond this time-
point.
Similarly we have taken parasitaemia at time-points beyond say
28 as a proxy for an effect on relapses or new infections. In order
to adequately assess this effect, the duration of follow-up needs
to be considerably longer than was used in these trials. Follow-
up of 42 days is only likely to include one relapse cycle and it is
therefore not possible to say whether this relapse is prevented or
simply delayed. In the trial with the longest follow-up (63 days)
there is some evidence that the advantage with ACTs may even
out over time (Phyo 2011 THA). In this trial over 50% of par-
ticipants treated with dihydroartemisinin-piperaquine had devel-
oped recurrent parasitaemia by day 63, compared to 80% follow-
ing chloroquine.
Quality of the evidence
We assessed the quality of the evidence using the GRADE ap-
proach and we presented the basis for the judgements in two
’Summary of findings’ tables (Summary of findings for the main
comparison; Summary of findings 2).
The evidence that ACTs are as effective as chloroquine (in settings
without substantial chloroquine resistance), is judged to be of high
quality; meaning we can have good confidence in this result and
further trials assessing this may be unnecessary. As chloroquine
resistance emerges, it is likely that ACTs will become superior.
The evidence that dihydroartemisinin-piperaquine has advantages
over other ACTs is judged to be of low or moderate quality, mean-
ing we can have some confidence in this result but further tri-
als will help to clarify this. We downgraded the evidence due to
concerns about the risk of bias of the trials (with high attrition
rates beyond day 28), and some inconsistency in the performance
of dihydroartemisinin-piperaquine (with high levels of recurrent
parasitaemias before day 28 seen in Papua New Guinea).
Potential biases in the review process
As we anticipated a lack of data, we decided to include participants
with P. vivax co-infections from trials of ACTs in P. falciparum.
These data are, however, very limited and they may be excluded
from future updates.
Agreements and disagreements with other
studies or reviews
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A recent review published in the Lancet Infectious Diseases
(Douglas 2010) included data from the same trials published here.
The authors concluded that:
’Several ACTs have high efficacy against asexual and sexual stages of P.
vivax both sensitive and resistant to chloroquine. Where chloroquine
resistance has emerged, long acting ACTs such as dihydroartemisinin
plus piperaquine and artesunate plus mefloquine will provide greater
postexposure prophylaxis against early recurrence of infection. This
advantage will become more pronounced as chloroquine resistance
increases.’
The findings of our review are consistent with this. However, it
should be noted that artesunate plus mefloquine has not been
directly compared to other ACTs in adequately powered trials.
The long half-life of mefloquine suggests that it may have similar
effectiveness to dihydroartemisinin-piperaquine but this has not
been shown.
Additionally, in the light of the findings from Papua NewGuinea,
we suggest caution in assuming the effectiveness of ACTs in the
presence of chloroquine resistance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
ACTs appear at least equivalent to chloroquine at effectively treat-
ing the blood stage of P. vivax infection. Even where chloroquine
remains effective this findingmay allow for simplified protocols for
treating all forms of malaria with ACTs. In settings where chloro-
quine is no longer effective, they offer an effective alternative.
Dihydroartemisinin-piperaquine is the most studied ACT and
may provide a longer period of post-treatment prophylaxis than
artemether-lumefantrine or artesunate plus amodiaquine. This
effect may be clinically important in high transmission settings
whether primaquine is also given or not.
Implications for research
There is now sufficient evidence to support the use of ACTs as an
alternative to chloroquine for effectively treating the blood stage
of P. vivax.
Further studies, with a longer duration of follow-up (six months
to one year), are required to adequately assess the nature of the
post-treatment prophylactic effect with dihydroartemisinin-piper-
aquine, artesunate plus mefloquine, artesunate plus sulphadoxine-
pyrimethamine and artesunate-pyronaridine. It is not clear from
the current studies whether the longer prophylactic effect persists
if participants are adequately treated with primaquine, whether
the relapse is simply delayed rather than prevented, or whether
this effect is associated with significant health benefits, such as a
reduction in clinical episodes or anaemia.
The evidence from Papua New Guinea (where chloroquine re-
sistance is common) is concerning in that treatment failures oc-
curred before day 14, even with the best performing ACT (di-
hydroartemisinin-piperaquine). This is a one-off finding, and the
same trial also found failure rates in P. falciparum that were higher
than seen anywhere else in the world. Further trials are needed to
confirm these data. In light of this, the efficacy of ACTs should not
be assumed in chloroquine-resistant areas but rather monitored
before and after any policy change.
The high proportion of recurrent parasitaemias in trials which
gave primaquine is surprising, and raises questions about the effec-
tiveness of the current regimen. The primaquine in the trials was
given unsupervised (as in real life) and it may be that these failures
are due to non-compliance rather than resistance. Further studies
of primaquine, and the newer tafenoquine, would be helpful.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ashley 2004 THA
Methods Trial design: A 3-arm randomized controlled trial (RCT)
Follow-up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started
Participants Number: 32 participants had P. vivax parasitaemia at baseline in treatment groups in-
cluded in this review, all were co-infections with P. falciparum (530 randomized in total)
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum parasitaemia, informed
consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, contraindication to mefloquine, treatment with mefloquine
in the previous 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and
48 hours
2. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervised
Primaquine was not given
Outcomes 1. Recurrent P. vivax parasitaemia at 14, 28, 42 and 63 days
Not included in this review:
1. Fever clearance time (not available for P. vivax patients only)
2. Parasite clearance time (not available for P. vivax patients only)
3. P. falciparum cure rate at day 63
4. P. falciparum gametocyte development during follow-up
5. Mean hematocrit at days 0 and 7 (not available for P. vivax patients only)
6. Adverse events (not available for P. vivax patients only)
Notes Country: Thailand
Setting: 4 rural clinics on the Thai-Myanmar border
Transmission: Low and unstable
Resistance: CQ resistance amongst P. vivax has not been widely reported in Thailand
Dates: Jul 2002 to Apr 2003
Funding: Wellcome Trust of Great Britain. DHA-P supplied by Holleykin Pharmaceu-
tical
Risk of bias
Bias Authors’ judgement Support for judgement
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Ashley 2004 THA (Continued)
Random sequence generation (selection
bias)
Low risk ’The randomisation was computer gener-
ated (STATA; version 7; Statacorp)’. Ran-
domized in blocks of 9
Allocation concealment (selection bias) Low risk ’The treatment allocation was concealed
in sealed envelopes labelled with the study
code’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived’. No other blinding described
Incomplete outcome data (attrition bias)
All outcomes
High risk The included sample size was very low. Al-
though attrition was low in absolute num-
bers they represent up to 50% of the P. vi-
vax patients.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk For the purpose of this review we are in-
cluding only a small subset of the original
randomized patients. This sample may not
therefore be truly randomized and the small
sample size means that prognostic balance
between groups is unlikely
Ashley 2005 THA
Methods Trial design: A 3-arm RCT
Follow-up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance for examination, symptom enquiry, malaria smear and hemat-
ocrit until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. Symptoms were screened at each visit
Participants Number: 47 participants had P. vivax parasitaemia at baseline and are included in this
review (499 randomized in total)
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum infection (only mixed
infections included in this review), informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, treatment with mefloquine in the previous 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and
48 hours
2. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
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Ashley 2005 THA (Continued)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 3 divided doses at 0, 24, and 48
hours
3. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervised
Primaquine was not given
Outcomes 1. Recurrence of P. vivax during follow-up at day 14, 28, 42, 63
Not included in this review:
1. Fever clearance (not available for P. vivax patients only)
2. Parasite clearance (not available for P. vivax patients only)
3. P. falciparum cure rate at days 63, 42, and 28, PCR adjusted and unadjusted
4. P. falciparum gametocyte development during follow-up
5. Mean hematocrit during follow-up (not available for P. vivax patients only)
6. Adverse events (not available for P. vivax patients only)
Notes Country: Thailand
Setting: 4 clinics on the Thai-Myanmar border
Transmission: Low and unstable
Resistance: CQ resistance amongst P. vivax has not been widely reported in Thailand
Dates: Apr 2003 to Apr 2004
Funding: Medicines for Malaria Venture, Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’The randomisation list was generated us-
ing STATA; version 7 (Stata)’. Randomized
in blocks of 9
Allocation concealment (selection bias) Low risk ’The treatment allocation was concealed
in sealed envelopes labelled with the study
code’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived’. No other blinding described
Incomplete outcome data (attrition bias)
All outcomes
Low risk The included sample size is very low. At-
trition is low in absolute numbers and un-
likely to have introduced significant bias
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk For the purpose of this review we are in-
cluding only a small subset of the original
randomized patients. This sample may not
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Ashley 2005 THA (Continued)
therefore be truly randomized and the small
sample size means that prognostic balance
between groups is unlikely
Awab 2010 AFG
Methods Trial design: An open-label RCT
Follow-up: Clinical assessment, blood smears and haemoglobin on days 0 to 3 then
weekly until day 56
Adverse event monitoring: Astandard symptom questionnaire at each visit
Participants Number: 536 randomized
Inclusion criteria: Febrile patients aged > 3 months, slide confirmed P. vivax mono-
infection, a negative pregnancy test, informed consent
Exclusion criteria: Pregnancy or lactation, clinical or laboratory features of severemalaria,
haemoglobin <7 g/dL, concomitant disease thatwouldmask treatment responses, known
allergy to study drugs, antimalarial treatment in the past month, anticipated inability or
unwillingness to complete the 56 day follow-up
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleypharm)
• Total dose: 6 mg/kg DHA and 48 mg/kg P in 3 divided doses over 3 days
2. Chloroquine (IDA)
• Total dose:25 mg base/kg in divided doses over 3 days
All doses supervised
Primaquine was not given
Outcomes 1. Recurrence of P. vivax during follow-up at day 14, 28, and 56
2. Fever clearance day 0 to 3
3. Parasite clearance day 0 to 3
4. Adverse events
Not included in this review:
1. Predictors of treatment failure
2. Gametocytemia at time of relapse
Notes Country: Afghanistan
Setting: 3 provincial malaria control centres, one in the east and two in the north
Transmission: Seasonal
Resistance: CQ resistance amongst P. vivax has not been widely reported in Afghanistan
Dates: Jul 2007 to Feb 2009
Funding: Mahidol-Oxford Research Unit, Thailand International Development and
Cooperation Agnecy, UK MRC Clinical Science Fellowship, Wellcome Trust of Great
Britain
Risk of bias
Bias Authors’ judgement Support for judgement
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Awab 2010 AFG (Continued)
Random sequence generation (selection
bias)
Low risk ’a pre-generated randomization list made
in blocks of 20 that was produced and held
independently of the field teams by a statis-
tician’
Allocation concealment (selection bias) Low risk ’The individual allocations were kept in
sealed opaque envelopes and opened only
after enrolment’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Patients and clinical field workers were not
blinded to the treatment arm after alloca-
tion. Microscopists were blinded to treat-
ment allocation at follow-up examinations’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: 25/268 (9.
3%) DHA-P versus 13/268 (4.9%) CQ
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
Hasugian 2007 IDN
Methods Trial design: An open label RCT
Follow-up: Daily until fever and parasites cleared then weekly until day 42, for a physical
examination, a symptom questionnaire and malaria film. Haemoglobin measured on
days 0, 7, 28 and day of failure
Adverse event monitoring: Assessed at each follow-up visit
Participants Number: 114 had P. vivax parasitaemia at baseline (340 randomized in total)
Inclusion criteria: Age > 1 yr, weight > 5 kg, slide confirmed malaria (P. falciparum, P.
vivax or both), fever or history of fever in the preceding 48 hours
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severe malaria, > 4%
red blood cells parasitized, concomitant disease that required hospital admission
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination:40 mg/320 mg (Artekin:
Holley)
• Total dose: 6.75 mg/kg DHA and 54 mg/kg PQP in 3 divided doses given once
daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax:Guilin, Flavoquine: Aven-
tis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervised
Both groups were offered an unsupervised course of Primaquine 0.3mg base/kg for 14
days, on completion of the study regimen
31Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hasugian 2007 IDN (Continued)
Outcomes 1. Parasitological failure with P. vivax on days 14, 28 and 42
Not included in the review:
1. Fever clearance (not available for P. vivax patients only)
2. Parasite clearance (not available for P. vivax patients only)
3. Parasitological failure due to P. falciparum
4. P. falciparum gametocyte carriage after treatment
5. Anaemia at day 0, 7, 28 (not available for P. vivax patients only)
6. Adverse events (not available for P. vivax patients only)
Notes Country: Indonesia
Setting: Rural clinics
Transmission: High
Resistance: CQ resistance among P. vivax is high at this study site
Dates: Jul 2005 to Dec 2005
Funding: Wellcome Trust - National Health and Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’A randomisation list was generated in
blocks of 20 by an independent statistician’
Allocation concealment (selection bias) Low risk ’Treatment allocation concealed in an
opaque, sealed envelope that was opened
once the patient had been enrolled’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’All slides were read by a certified micro-
scopist who was blinded to treatment allo-
cation’. An open label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk The primary outcomedata are unpublished
data including only participants with P. vi-
vax mono-infection at baseline. Attrition
although balanced between groups was >
15% at day 28 and > 20% at day 42
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
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Hutagalung 2005 THA
Methods Trial design: An open-label RCT
Follow-up: Examination and malaria film daily until fever and parasites cleared then
weekly to day 42 or any other day they became unwell
Adverse event monitoring: At each visit a questionnaire on adverse events was completed
Participants Number: 24 participants had P. vivax co-infections at baseline (490 randomized)
Inclusion criteria: Weight > 10 kg, slide confirmed P. falciparum +/- P. vivax, informed
consent
Exclusion criteria: Pregnancy, clinical or laboratory signs of severe illness and/or severe
and complicated malaria severe malaria, treatment with mefloquine in previous 63 days
Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• < 15 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
• Plus glass of chocolate milk with each dose
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilan, Lariam: Hoff-
man-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
All doses supervised
Primaquine not given
Outcomes 1. P. vivax parasitaemia on days 0 to 3
2. P. vivax recurrence at days 14 and 28
Not included in the review:
1. Fever clearance (P. falciparum)
2. Parasite clearance (P. falciparum)
3. Gametocyte clearance (data only for P. falciparum)
4. Failure due to P. falciparum
5. Adverse events
Notes Country: Thailand
Setting: Malaria clinics of the Shoklo Malaria Research Unit
Transmission: Low and unstable
Resistance: CQ resistance amongst P. vivax has not been widely reported in Thailand
Dates: July 2001 to June 2002
Funding: Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Computerized randomisation was in
blocks of ten’.
Allocation concealment (selection bias) Unclear risk None described.
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Hutagalung 2005 THA (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk An open label trial. No comment on blind-
ing of laboratory staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk The included sample size is very low. Attri-
tion was low in absolute numbers and un-
likely to have significantly biased the result
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk For the purpose of this review we are in-
cluding only a small subset of the original
randomized patients. This sample may not
therefore be truly randomized and the small
sample size means that prognostic balance
between groups is unlikely
Karunajeewa 2008 PNG
Methods Trial design: A 4-arm open label RCT
Follow-up: Standardized follow-up including temperature and malaria film on days 0,
1, 2, 3, 7, 14, 28, and 42. Drug levels assayed on day 7
Adverse event monitoring: None described
Participants Number: 195 had P. vivax parasitaemia at baseline (372 randomized in total)
Inclusion criteria: Age 0.5 to 5 years, axillary temp > 37.5 ºC or history of fever in the
preceding 24 hours, > 1000/µL asexual P. falciparum or > 250/µL asexual P. vivax, P.
ovale or P. malariae, informed consent
Exclusion criteria: Features of severe malaria, evidence of another infection or coexisting
condition including malnutrition, intake of study drug in previous 14 days
Interventions 1. Artesunate plus sulphadoxine-pyrimethamine, loose combination (Sanofi-Aventis,
Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
2. Dihydroartemisinin-piperaquine, fixed dose combination: 40 mg/320 mg (Beijing
Holley-Cotec)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
3. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Novartis), given
with milk
• A 1.7 mg/kg twice daily for 3 days
• L 10 mg/kg twice daily for 3 day
4. Chloroquine plus sulphadoxine-pyrimethamine, loose combination (Aspen Health-
care, Roche)
• CQ 10 mg base/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
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Karunajeewa 2008 PNG (Continued)
All doses supervised except the evening dose of AL6
Primaquine was not given
Outcomes 1. Recurrence of P. vivax at day 14, 28, and 42
2. Fever clearance
3. Parasite clearance
Not included in this review:
1. Drug levels day 7
2. ACPR (P. falciparum) at days 28 and 42, PCR adjusted and unadjusted
3. P. falciparum gametocyte prevalence during follow-up
4. Adverse events (not available for P. vivax patients only)
Notes Country: Papua New Guinea
Setting: Health centres
Transmission: High
Resistance: CQ resistance among P. vivax rising since 1980s
Dates: Apr 2005 to Jul 2007
Funding: WHOWestern Pacific Region, Rotary against Malaria in Papua New Guinea,
National Health and Medical Research Council of Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Computer-generated randomised assign-
ment with blocks of 24 for each site’
Allocation concealment (selection bias) Low risk Information from authors - allocation was
concealed in sealed opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’All blood smears were subsequently reex-
amined independently by two skilled mi-
croscopists who were unaware of the treat-
ment assignments’. An open label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition was high (> 10%) in all groups
and could have introduced bias into the
result
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
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Kolaczinski 2007 AFG
Methods Trial design: An open label RCT
Follow-up: Clinical symptoms, temperature and malaria film recorded on days 0, 1, 2,
3, 7, 14, 28, 42 and when ill. PCV recorded on Day 0, and day 28 or day of failure
Adverse event monitoring: None described
Participants Number: 190 randomized
Inclusion criteria: Age > 2 years, Weight > 5 kg, microscopically confirmed P. vivax
mono-infection > 1 asexual parasite per 10 fields, informed consent
Exclusion criteria: Pregnancy, severemalaria, evidence of concomitant infectionor serious
disease, recent use of antimalarial drugs, known allergy to study drugs
Interventions 1. Artesunate plus sulphadoxine-pyrimethamine, loose combination (Plasmotrim,
Mepha: Fansidar, Roche)
• AS 4 mg/kg once daily for 3 days
• SP 25/1.25 mg/kg once on the first day
2. Chloroquine (Nivaquine; Beacon)
• CQ 25 mg/kg given over 3 days
All doses supervised
Primaquine was not given
Outcomes 1. Recurrence of P. vivax at day 14, 28, and 42
2. PCV on day 0 and 28 or day of failure
3. Fever clearance
4. Parasite clearance
5. Gametocytemia
6. Adverse events
Notes Country: Afghanistan - Jalalabad, Nangahar Province
Setting: Malaria reference centre
Transmission: Seasonal and unstable
Resistance: Substantial CQ resistance has not been reported from Afghanistan (Author
communication)
Dates: Mar 2004 to Aug 2004
Funding: UNDP, World Bank, WHO Special Programme for Research on Tropical
Disease
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’A computer-generated randomisation list
(generated using Microsoft Excel; Mi-
crosoft Corp., Redmond, WA, USA) was
used to randomly assign vivax cases within
gender and age groups to one of two treat-
ment regimens’
Allocation concealment (selection bias) High risk ’After determining suitability for inclusion,
the study clinician enrolled each patient
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Kolaczinski 2007 AFG (Continued)
and allocated them to the treatment arm
next indicated in the randomisation list.
The allocation sequence was not concealed
from the study clinician’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’The clinical assistants responsible for di-
rectly observed treatment and clinical as-
sessment during follow-up were blind to
the nature of the treatment arms but were
aware of the arm code to which patients
were allocated (e.g. ‘arm 1’, ‘arm 2’; dif-
ferences in dosages and tablet appearance
would not have allowed complete conceal-
ment). The microscopists and laboratory
technicians were blind to treatment alloca-
tions’
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 participants were lost to follow-up with
similar numbers in each group. This is un-
likely to have a major effect on the result
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
Krudsood 2007 THA
Methods Trial design: An open label RCT
Follow-up: Admitted to hospital for 28 days. Temperature and malaria film recorded
every 12 hours until parasite and fever clearance then on days 3, 7, 14, 21, and 28
Adverse event monitoring: None described
Participants Number: 98 randomized
Inclusion criteria: Age > 15 years, Weight > 40 kg, microscopically confirmed P. vivax
mono-infection, informed consent
Exclusion criteria: Pregnancy or lactation, severe malaria, concomitant febrile illness,
severe malnutrition, ingestion of antimalarial drugs in the past 14 days, known allergy
or intolerance to study drugs
Interventions 1. Artemether-lumefantrine, fixed-dose combination: 120/20 mg (Coartem, Novartis)
• AL 4 tablets at 0, 8, 24, 32, 48, and 60 hours
2. Chloroquine (Government Pharmaceutical Organisation)
• CQ 25mg/kg given over 3 days
All doses supervised
Both regimens received additional primaquine (Government Pharmaceutical Organiza-
tion)
• PQ 15 mg daily for 14 days
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Krudsood 2007 THA (Continued)
Outcomes 1. Recurrence of P. vivax at day 14 and 28
2. Fever clearance
3. Parasite clearance
4. Serious adverse events
5. Other adverse events (text summary only)
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low endemicity
Resistance: CQ resistance amongst P. vivax has not been widely reported in Thailand
Dates: Jun 2004 to May 2005
Funding: WHO, Ministry of Health, Labor, and Welfare of Japan, and Mahidol Uni-
versity Research Grants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’The patients were randomly assigned’, no
further description
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up were high in
both groups 18%
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
Phyo 2011 THA
Methods Trial design: Assessor blind RCT
Follow-up: daily until afebrile and aparasitaemic and then weekly until day 63. Temper-
ature, malaria film, hematocrit, and chloroquine plasma concentration at every visit
Adverse event monitoring: At each visit a symptom questionnaire was completed
Participants Number: 500 randomized
Incusion criteria: Age > 1 yr; Body weight > 5 kg; Microscopically confirmed monoin-
fection of P. vivax parasitaemia (> 5/500 WBC); Febrile (axillary temperature, > 37.5
°C) or had history of fever
Exclusion criteria: Known hypersensitivity to the study drugs; intercurrent illness; preg-
nant, lactating; severely anaemic (hematocrit < 20%); received mefloquine in the past
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Phyo 2011 THA (Continued)
60 days; received dihydroartemisinin piperaquine in the past 3 months
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Duoco-
texin: Holley)
• Total target dose: DHA 7 mg/kg + P 55 mg/kg in 3 divided doses, given once
daily for 3 days with milk.
2. Chloroquine (Government Pharmaceutical Organization, Thailand)
• Target dose: 25 mg base/kg in three divided doses, given once daily for 3 days
All patients with normal G6PD were administered Primaquine at the target dose of 0.5
mg/kg/day for a period of 14 days at the end of the follow-up period
Outcomes 1. Recurrence of P. vivax on day 28, 63
2. Fever clearance
3. Parasite clearance within 24, 48, 72, and 96 hours
4. Adverse events
Notes Country: Thailand-Myanmar border
Setting: Malaria Research Unit Clinic
Transmission: low and seasonal
Resistance: Decreased susceptibility to CQ in some isolates.
Dates: Jan 2007 to Dec 2008
Funding: Holley Pharm; Wellcome Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Pateints were allocated to the treatment
arms on a pre generated randomization list
in blocks of 20’
Allocation concealment (selection bias) Low risk ’The individual allocations were concealed
in sealed envelopes and opened only after
enrollment’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Patients and clinic workers were not
blinded. Laboratory technicians were un-
aware of treatment allocation’
Incomplete outcome data (attrition bias)
All outcomes
Low risk 35 lost to follow-up or excluded from anal-
ysis in the DHA-P arm (14%) and 37(14.
8%) lost to follow-up or excluded from the
chloroquine arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
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Poravuth 2010 ASIA
Methods Trial design: Double-blind RCT
Follow-up: All participants were hospitalized for 3 days then seen for follow-up at day
7, 14, 21, 28, 35, and 42
Adverse event monitoring: Monitored throughout the study, 12-lead ECGs at day 0 2,
7, 14, and 42 if clinically indicated, laboratory tests at day 0, 3, 7, 28, and 42 if clinically
indicated
Participants Number: 456 randomized
Inclusion criteria: Age 3 to 60 years, weight 20 to 90 kg, uncomplicated P. vivax mono-
infection with a parasite density > 250 mL, fever or documented history of fever in the
previous 24 hours
Exclusion criteria: pregnancy or lactation, any other condition requiring hospitalisation;
haemoglobin < 8 g/dL; hepatic or renal impairment; malnutrition; presence or history
of clinically significant disorders; known hypersensitivity to study drugs; known active
hepatitis A IgM, hepatitis B surface antigen, hepatitis C antibody or seropositive for HIV
antibody; used an antimalarial within the previous two weeks; used an antibacterial with
anti-malarial activity within the previous two weeks
Interventions 1. Artesunate-pyronaridine, fixed-dose combination 60 mg/180 mg (Shin Poong)
• 20 kg to 25 kg 1 tablet once daily for 3 days
• 26 kg to 44 kg 2 tablets once daily for 3 days
• 45 kg to 64 kg 3 tablets once daily for 3 days
• 65 kg to 90 kg 4 tablets once daily for 3 days
• Target dose
2. Chloroquine tablets 155 mg (Shin Poong)
• Adult target dose 620 mg on Days 0 and 1 and 310 mg on Day 2.
• Child target dose 10 mg/kg on Days 0 and 1 and 5 mg/kg onDay 2.
All doses supervised
Primaquine was given for 14 days starting on day 28
Outcomes 1. Recurrence of P. vivax at day 14, 28, and 42
2. Median time to parasite clearance/parasitaemia on days 1, 2, and 3.
3. Median time to fever clearance/fever on days 1, 2, and 3.
4. Adverse events
Notes Country: 5 study sites in Cambodia, Thailand, India and Indonesia
Setting: Local hospitals
Transmission: Not stated
Resistance: Not stated
Dates: Mar 2007 to Mar 2008
Funding: Shin Poong Pharmaceutical Company, Seoul, Republic of Korea, and the
Medicines for Malaria Venture, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’A computer-generated randomization
scheme was provided by the sponsor’
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Poravuth 2010 ASIA (Continued)
Allocation concealment (selection bias) Low risk ’Randomization numbers were assigned in
ascending order to each subject according
to the order recruited. The subject was allo-
cated an individually numbered treatment
pack, which contained sufficient tablets for
3 days’ therapy plus an overage bottle con-
taining tablets in case the subject vomited
the first dose’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Study drugs were administered on a dou-
ble-blind, double-dummy basis. The inves-
tigator calculated the appropriate dose and
study drug was administered by a different
member of staff, designated by the inves-
tigator. All study investigators, laboratory
technicians andpatientswere blind to treat-
ment assignment. Active drugs and place-
bos were packaged similarly’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of participants lost to follow-up
was low and balanced between groups: 4%
AS-Py versus 8% CQ
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk ’The study sponsors were responsible for
data collection, statistical analysis and in-
terpretation’
Ratcliff 2007 IDN
Methods Trial design: An open-label RCT
Follow-up: A symptom questionnaire, physical examination, malaria film and haemo-
globin measurement daily until fever and parasites cleared then weekly to day 42
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number: 175 had P. vivax parasitaemia at baseline (774 randomized in total)
Inclusion criteria: Weight >10 kg, fever or a history of fever in the preceding 48 hrs, slide
confirmed malaria (P. falciparum, P. vivax or mixed infections)
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severity, parasitaemia
> 4%, concomitant disease requiring hospital admission
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
• Total dose: DHA 6.75 mg/kg + P 54 mg/kg in 3 divided doses, given once daily
for 3 days
2. Artemether-lumefantrine, fixed-dose combination: 20 mg/120 mg (Coartem: Novar-
tis)
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Ratcliff 2007 IDN (Continued)
• 10 kg to 15 kg 1 tablet twice daily for 3 days
• 15 kg to 25 kg 2 tablets twice daily for 3 days
• 25 kg to 35 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
Only the first dose of each day was supervised. All participants advised to take each dose
with a biscuit or milk
All patients were also given primaquine
• PQ 0·3 mg base/kg 14 days starting on day 28
Outcomes 1. P. vivax recurrence at day 14, 28, and 42
Not included in the review:
1. Fever clearance (not available for P. vivax patients only)
2. Parasite clearance (not available for P. vivax patients only)
3. P. falciparum at days 42 and 28, PCR adjusted and unadjusted
4. P. falciparum gametocyte carriage after treatment
5. Anaemia during follow-up (not available for P. vivax patients only)
6. Adverse events (not available for P. vivax patients only)
Notes Country: Indonesia
Setting: Rural outpatient clinics
Transmission: High
Resistance: CQ resistance is high at this study site
Dates: Jul 2004 to Jun 2005
Funding: Wellcome Trust UK and National Health and Medical Research Council Aus-
tralia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’A randomisation list was generated in
blocks of 20 patients by an independent
statistician’
Allocation concealment (selection bias) Low risk ’Treatment allocation concealed in an
opaque sealed envelope that was opened
once the patient had been enrolled’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’All slides were read by a certified micro-
scopist with at least 10 years experience,
who was blinded to treatment allocation’.
No other blinding was conducted
Incomplete outcome data (attrition bias)
All outcomes
High risk The primary outcome data are unpub-
lished data including only participants with
P. vivax mono-infection at baseline. Attri-
tion although balanced between groupswas
>10% at day 28 and >15% at day 42
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Ratcliff 2007 IDN (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias detected.
Smithuis 2006 MMR
Methods Trial design: A 4-arm open-label RCT
Follow-up: A symptom questionnaire, malaria film, and gametocyte count on days 0, 1,
2, 3, 7, 14, 21, 28, 35, and 42. Haemoglobin was measured on days 0 and 28
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number: 87 patients had P. vivax parasitaemia at baseline (652 randomized in total)
Inclusion criteria: Age > 1 year, axillary temperature > 37.5 ºC or history of fever in
the previous 48 hours, P. falciparummono-infection 500 to 100,000 parasites/µL or co-
infection with P. vivax, informed consent
Exclusion criteria: Pregnancy, signs of severe malaria, signs or symptoms of other diseases,
history of taking mefloquine in the previous 2 months or any other antimalarial in the
previous 48 hours, history of psychiatric disease
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Supervised
2. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Artekin:
Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Unsupervised
3. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Supervised
4. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Unsupervised
Primaquine was not given
Outcomes 1. P. vivax recurrence at day 14, 28, and 42
2. Fever clearance
3. Parasite clearance
4. Mean change in haemoglobin from day 0 to day 28
Not included in the review:
1. P. falciparum at days 42 and 28, 42 PCR unadjusted and PCR adjusted
2. P. falciparum gametocyte appearance at day 7 and day 14
43Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smithuis 2006 MMR (Continued)
3. P. falciparum gametocyte carriage at days 0, 7, 14, 21, and 28
4. Adverse events (not available for P. vivax patients only)
Notes Country: Myanmar
Setting: Rural village tracts
Transmission: Low and seasonal
Resistance: CQ resistance amongst P. vivax has not been widely reported in Myanmar
Dates: Nov 2003 to Feb 2004
Funding: Médecins sans Frontières (Holland)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’At both study locations three boxes were
prepared, one for each of the three age
groups, by an administrator whowas other-
wise not connected with the study. In each
box, 40 unmarked and sealed opaque en-
velopes were deposited. Each envelope con-
tained a card that described the treatment
assignment, and each treatment allocation
had an equal number of cards (ten). Each
new patient (or his or her carer) was asked
to take one of the envelopes from the box
for their age group. Treatmentwas then dis-
pensed in accordance with the treatment
allocation in the envelope.Whenever a box
became empty, another 40 envelopes were
put in that box’
Allocation concealment (selection bias) Low risk See above.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk An open label trial. No comment on blind-
ing of laboratory staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk The included sample size is low. Attrition
is low in absolute numbers and unlikely to
have introduced significant bias
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk For the purpose of this review we are in-
cluding only a small subset of the original
randomized patients. This sample may not
therefore be truly randomized and the small
sample size means that prognostic balance
between groups is unlikely
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Smithuis 2010 MMR
Methods Trial design: A 10-arm RCT
Follow-up: Patients were asked to return weekly for 9 weeks for assessment and at any
other time they were unwell. Haemoglobin was measured on days 0 and 63
Adverse event monitoring: Not described
Participants Number: 66 participants had P. vivax co-infections at baseline and are included in this
review. The participants who received the one-off dose of primaquine are excluded from
this review
Inclusion criteria: Age > 6 months, weight > 5 kg, P. falciparum mono-infection 500 to
200,000 parasites/µL or co-infection with P. vivax, informed consent
Exclusion criteria: Pregnancy, signs of severe malaria, severe malnutrition, history of
hypersensitivity to any of the study drugs, severe malnutrition, concomitant febrile
illness, history of psychiatric disorder, a full course of mefloquine in the previous 9 weeks
or any other antimalarial in the previous 48 hours
Interventions Each of the five study arms were also divided into two where one half also received a
one-off dose of 0.75 mg/kg primaquine
1. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg or 20 mg/
160 mg tablets (Artekin: Holleykin)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
2. Artesunate plus amodiaquine, fixed dose combination: 25 mg/67.5 mg or 50 mg/135
mg or 100 mg/270 mg tablets
• AS 4 mg/kg once daily for 3 days
• AQ 10.8 mg base/kg once daily for 3 days
3. Artemether-lumefantrine, fixed dose combination: 20 mg/120 mg tablets
• A 3.3 mg/kg in two divided doses each day for 3 days
• L 19.8 mg/kg in two divided doses each day for 3 days
• Plus advised to consume fatty food or breast feed before each dose
4. Artesunate plus mefloquine, fixed dose combination: 25 mg/55 mg or 100 mg/220
mg tablets (artesunate: Guilin, Lariam: Hoffman-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 8.8 mg/kg once daily for 3 days
5. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
First dose supervised, all others unsupervised.
Primaquine was not given
Outcomes 1. Recurrent parasitaemia at day 14, 28, 42, and 63
Not included in the review:
1. Failure due to P. falciparum
2. Gametocytemia (not available for P. vivax patients only)
3. Haemoglobin (not available forP. vivax patients only)
4. Adverse events
45Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smithuis 2010 MMR (Continued)
Notes Country: Myanmar
Setting: Clinics
Transmission: Not described
Resistance: CQ resistance amongst P. vivax has not been widely reported in Myanmar
Dates: Dec 2008 to March 2009
Funding: Médecins sans Frontières (Holland)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’They were stratified prospectively into
three age groups...patients were randomly
assigned in equal numbers to receive one of
the five different treatments’
Allocation concealment (selection bias) Low risk ’Treatment allocations were put in sealed
envelopes in blocks of 50 for each age-
group...patients drawing an envelope from
a box after enrolment’
Blinding (performance bias and detection
bias)
All outcomes
Low risk An open label trial. ’Microscopists examin-
ing blood films were unaware of treatment
allocation’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition is low in absolute numbers and
unlikely to have introduced significant bias
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk For the purpose of this review we are in-
cluding only a small subset of the original
randomized patients. This sample may not
therefore be truly randomized and the small
sample size means that prognostic balance
between groups is unlikely
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Sutanto 2013 IDN
Methods Trial design: An open-label RCT
Follow-up: Routine blood films were taken on days 3, 7, 14, 21, 28, 35, 41, 56, 63, 70,
84, 126, 140, 180, and 365, plus other visits to the clinic with illness
Adverse event monitoring: Symptom questionnaire and hematology and biochemistry
investigations (WBC, RBC,MCV,MCHC, LFT, RFT, gamma glutathione hydroxylase,
pyruvic transaminase, creatine kinase, serum electrolytes, G6PD) were performed on
days 3, 7, 14, 28, 41, and 84
Participants Number: 116 randomized (41, 39, and 36 in each of the three arms)
Inclusion criteria: Indonesian soldiers after a year of duty in malarious Papua, Indonesia
diagnosed with P. Vivax malaria by microscopy
Exclusion criteria: Refusal to consent; any condition requiring hospitalization; G6PD
deficiency; SGOT, SGPT > 2.5 times upper limit of normal; QTcF > 450ms; anaemia
(haemoglobin < 8 g/dL); definite plans for absence from the site in 28 days
Interventions 1. Quinine 200mg tablets (Quinine: Kimia Pharma)
• 10 mg/kg three times daily for 7 days
• Plus primaquine 30 mg daily for 14 days, starting from day 0 (45 mg if weight >
70 kg)
2. Dihydroartemisinin-piperaquine, fixed-dose combination: 40 mg/320 mg (Eu-
rartemisim: Sigma Tau)
• Three tablets once daily for three days
• Plus primaquine 30 mg daily for 14 days, starting from day 28 (45 mg if weight >
70 kg)
The third study arm received artesunate alone and was excluded from this review
Outcomes 1. Recurrence of P. vivax at day 28
2. Recurrence of P. vivax between days 29 to 163
3. Parasite clearance at 72 hours
4. Anaemia
5. Adverse events
Notes Country: Indonesia
Setting: Army base
Transmission: Soldiers had returned from endemic Papua, Indomesia to East Java, In-
donesia where there is no endemic P. vivax.
Resistance: CQ resistance amongst P. vivax is prevalent in Papua
Dates: Enrolment Nov 2010 to Apr 2011
Funding:Medicines forMalariaVenture,WellcomeTrust. SigmaTauprovided theDHA-
P
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’A randomized list of study numbers that
were block allocated was generated by vary-
ing the blocking number at random’
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Sutanto 2013 IDN (Continued)
Allocation concealment (selection bias) Low risk ’An envelope revealing the assigned therapy
was opened after informed consent’
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk An open label trial. No comment on blind-
ing of laboratory staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three were lost to follow-up in the quinine
+ primaquine arm (8%) and none in the
other two arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of any other bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Batty 1998 No ACT given. A pharmacokinetic study of artesunate monotherapy
Betuela 2012 There was no arm that has received ACT.
Dao 2007 Not randomized. A single arm study of artesunate plus primaquine
Davis 2011 This study is a cost-effectiveness study already published in NEJM in 2008. We included the data from this
study in the previous review
Douglas 2010 A review article, not a RCT.
Hamedi 2004 No ACT given. An RCT of artesunate plus primaquine versus chloroquine plus primaquine
Hombhanje 2009 Participants did not have uncomplicated P. vivax at baseline. An RCT of artesunate-naphthoquine versus
chloroquine plus sulfadoxine-pyrimethamine in P. falciparum malaria.
Leang 2013 Although the study reports outcome measures for different arms including one with ACT, there is no
mention on whether the study is randomized
Luxemburger 1996 Not randomized. Trial authors gave all participants with P. vivax a single dose of mefloquine.
Naing 2010 Review article.
Price 2007a Uses data from Hasugian 2007 IDN and Ratcliff 2007 IDN. No new efficacy or safety data.
Pukrittayakamee 2000 No ACT given. A RCT of eight different monotherapies.
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Rueangweerayut 2012 The participants of this study had only P. falciparum infection.
Senn 2013 This study is on intermittent preventive treatment in infants (IPTi)
Thimasarn 1997 Participants did not have uncomplicated P. vivax malaria. RCT of different treatment combinations for P.
falciparum.
Tjitra 2002 Not randomized. Two separate trials are reported: a quasi-RCT of chloroquine versus chloroquine plus
sulfadoxine-pyrimethamine, followed by a single arm study of artesunate plus sulfadoxine-pyrimethamine
Tjitra 2012 Trial authors only gave the comparator artemisinin-napthoquine as a single dose ACT
van Vugt 1998 Artesunate plus mefloquine versus a four-dose course of artemther-lumefantrine. This regimen is no longer
recommended as it was shown to be inferior to six doses for treating P. falciparum.
Yeshiwondim 2010 No participants received ACT.
Yohannes 2011 Quasi-RCT: alternate allocation.
Zwang 2009 An individual patient data meta-analysis of six clinical trials including Ashley 2004 THA, Ashley 2005
THA, Janssens 2007a, Smithuis 2010 MMR and two other trials which did not include patients with P.
vivax at baseline. No new efficacy data.
Characteristics of studies awaiting assessment [ordered by study ID]
Janssens 2007
Methods Trial design: Open label RCT
Follow-up: Monitored daily until fever and parasites cleared then weekly to day 63. Temperature, symptom ques-
tionnaire, malaria film, and hematocrit at each visit
Adverse event monitoring: An adverse event defined as any new sign or symptom appearing after treatment started.
At each visit a symptom questionnaire was completed
Participants Number: It is unclear whether any participants had P. vivax infection at baseline (464 randomized in total)
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 ºC or history of fever, signs and symptoms of uncomplicated
malaria, P. falciparum mono or mixed infections, written informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% red blood cells parasitized, a
history of convulsions or neuropsychiatric disorder, treatment with mefloquine in the past 60 days
Interventions 1. Dihydroartemisinin-piperaquine, fixed-dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Adult total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses, given at 0, 8, 24, and 48 hours
• Children total dose: 6.4 mg/kg DHA + 51.2 mg/kg P in 4 divided doses, given at 0, 8, 24, 48 hours
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilin, Mefloquine: Mepha)
• Adults: 100 mg AS plus 500 mg MQ twice daily on day 0, then 200 mg AS once daily on day 1 and day 2
• Children: AS 4 mg/kg once daily for 3 days plus 25 mg/kg MQ split into 2 doses on day 0
All doses supervised
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Janssens 2007 (Continued)
Primaquine was not given
Outcomes 1. P. vivax recurrence at day 14, 28, 42 and 63
Not included in the review:
1. Fever clearance (not available for P. vivax patients only)
2. Parasite clearance (not available for P. vivax patients only)
3. P. falciparum at days 63, 42, and 28, PCR adjusted and unadjusted
4. Mean hematocrit at day 0 and 63 (not available for P. vivax patients only)
5. Adverse effects (not available for P. vivax patients only)
Notes Country: Cambodia
Setting: Rural health centres and outreach malaria clinics
Transmission: Low and seasonal
Resistance: Not stated
Dates: Oct 2002 to March 2003
Funding: Médecins sans Frontières
Shin 2011
Methods Trial design: Randomized, double-blind, double-dummy, comparative study
Inclusion criteria: Age between 3 and 60 years; body weight between 20 and 90 kg; acute uncomplicated P. vivax
mono-infection confirmed with fever and positive microscopy of P. vivax with parasite density = 250/µL of blood
and a rapid negative test for P. falciparum.
Participants Number: 30
Interventions Pyronaridine (180 mg) + artesunate (60 mg) once a day for 3 days
Chloroquine (155 mg) once a day for 3 days
Outcomes 1. Cure rate at Day 14
2. Proportion of patients cured at day 28 and day 42
3. Parasite clearance time
4. Fever clearance time
5. Proportion of patients aparasitaemic on days 1, 2 and 3
6. Adverse events
Notes This is a conference abstract and no details of either the study or the contact information of the authors are available
van Vugt 2002
Methods Trial design: Open label RCT
Follow-up: Monitored daily until fever and parasites cleared then weekly to day 42. Clinical examination, symptom
questionnaire, malaria film, and hematocrit at each visit
Adverse event monitoring: At each visit a symptom questionnaire was completed
Participants Number: It is unclear whether any participants had P. vivax infection at baseline (1596 were randomized in total)
Inclusion criteria: Weight >10 kg, slide confirmed acute P. falciparum malaria, written informed consent
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van Vugt 2002 (Continued)
Exclusion criteria: Pregnancy, not obtunded or vomiting, no other clinical or laboratory signs of severe illness,
treatment with mefloquine in the past 63 days
Interventions 1. Artesunate plus mefloquine, loose combination
• AS 4mg/kg once daily for 3 days
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2
2. Artesunate plus atavoquone-proguanil
• AS 4 mg/kg once daily for 3 days
• Atavoquine 15 mg/kg once daily for 3 days
• Proguanil 8 mg/kg once daily for 3 days
3. Atavoquone-proguanil
• Atavoquine 15 mg/kg once daily for 3 days
• Proguanil 8 mg/kg once daily for 3 days
All doses supervised
Primaquine was not given
Outcomes 1. P. vivax recurrence by day 42
Not included in the review:
1. Parasite clearance
2. P. falciparum at days 42, and 28, PCR adjusted and unadjusted
3. Gametocyte carriage
4. Adverse effects (not available for P. vivax patients only)
Notes Country: Thailand
Setting: Malaria clinics of the Shoklo Malaria Research Unit
Transmission: Low transmission
Resistance: Not stated
Dates: July 1998 to July 2000
Funding: Atavoquine-proguanil was donated by Glaxo-SmithKline. The Wellcome Trust of Great Britain
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D A T A A N D A N A L Y S E S
Comparison 1. ACT versus Chloroquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasite clearance 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Remaining parasitaemic
after 24 hours
4 1652 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.36, 0.50]
1.2 Remaining parasitaemic
after 48 hours
4 1648 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.05, 0.74]
1.3 Remaining parasitaemic
after 72 hours
4 1648 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.01, 0.43]
2 Fever clearance 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Remaining febrile after 24
hours
2 990 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.43, 0.70]
2.2 Remaining febrile after 48
hours
3 1390 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.31, 0.91]
2.3 Remaining febrile after 72
hours
2 985 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.27, 1.36]
3 Recurrence of parasitaemia 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Before day 14 1 427 Risk Ratio (M-H, Random, 95% CI) 2.88 [0.12, 70.22]
3.2 Before day 28 5 1622 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.18, 1.90]
3.3 After day 28 (primaquine
not given)
3 1066 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.40, 0.82]
3.4 After day 28 (primaquine
given)
1 376 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.08, 0.94]
3.5 During full follow-up
period (42 or 56 days)
4 1460 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.44, 0.78]
4 Gametocytemia 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 On Day 0 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 On Day 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 On Day 2 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 On Day 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Serious adverse events 5 1775 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.14, 7.04]
Comparison 2. ACT versus Chloroquine plus Sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasite clearance 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Remaining parasitaemic
after 24 hours
1 195 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.15, 0.34]
1.2 Remaining parasitaemic
after 48 hours
1 195 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.03, 0.27]
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1.3 Remaining parasitaemic
after 72 hours
1 195 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.03, 0.81]
2 Fever clearance 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Remaining febrile after 24
hours
1 195 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.75, 1.48]
2.2 Remaining febrile after 48
hours
1 195 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.31, 1.23]
2.3 Remaining febrile after 72
hours
1 195 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.29, 2.02]
3 Recurrence of parasitaemia 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Before day 14 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Before day 28 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 After day 28 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 During full follow-up
period (42 days)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Serious adverse events 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. ACT versus Quinine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasite clearance 1 72 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.09]
1.1 Remaining parasitaemia
after 72 hours
1 72 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.09]
2 Recurrence of parasitaemia 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Before day 14 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Before day 28 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 After day 28 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 During full follow-up
period (42 days)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. ACT versus ACT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remaining parasitemic after 24
hours
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 DHA-P versus AS+MQ 3 120 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.28, 4.92]
1.2 DHA-P versus AL6 1 83 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.31, 1.94]
1.3 AS+MQ versus AL6 1 24 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.60, 1.72]
1.4 DHA-P versus AS+SP 1 95 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.49, 3.72]
2 Remaining parasitemic after 48
hours
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 DHA-P versus AS+MQ 3 120 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 DHA-P versus AL6 1 83 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.04, 4.70]
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2.3 AS+MQ versus AL6 1 24 Risk Ratio (M-H, Random, 95% CI) 5.13 [0.29, 89.57]
2.4 DHA-P versus AS+SP 1 95 Risk Ratio (M-H, Random, 95% CI) 3.47 [0.14, 83.00]
3 Remaining febrile after 24 hours 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 DHA-P versus AL6 1 83 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.83, 2.33]
3.2 DHA-P versus AS+SP 1 95 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.64, 1.40]
4 Remaining febrile after 48 hours 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 DHA-P versus AL6 1 83 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.22, 1.83]
4.2 DHA-P versus AS+SP 1 95 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.41, 5.06]
5 Recurrent parasitaemia before
day 28
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 DHA-P versus AS+MQ 4 186 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.45]
5.2 DHA-P versus AL6 3 237 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.04, 0.58]
5.3 DHA-P versus AS+AQ 2 108 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.00, 0.73]
5.4 DHA-P versus AS+SP 1 77 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.15, 0.72]
5.5 AS+MQ versus AL6 2 56 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.40]
5.6 AS+MQ versus AS+AQ 1 34 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.7 AL6 versus AS+AQ 1 28 Risk Ratio (M-H, Random, 95% CI) 16.06 [1.03, 249.60]
5.8 AL6 versus AS+SP 1 72 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.67, 1.68]
6 Recurrent parasitaemia after day
28
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 DHA-P versus AS+MQ 4 169 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.09]
6.2 DHA-P versus AL6 3 168 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.11, 1.38]
6.3 DHA-P versus AS+AQ 2 95 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.12, 2.40]
6.4 DHA-P versus AS+SP 1 50 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.14, 1.38]
6.5 AS+MQ versus AL6 2 45 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.61, 1.37]
6.6 AS+MQ versus AS+AQ 1 36 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.72, 1.55]
6.7 AL6 versus AS+AQ 1 18 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.68, 1.80]
6.8 AL6 versus AS+SP 1 38 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.29, 1.84]
7 Recurrent parasitaemia during
full follow-up period (0 to 42
or 63 days)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 DHA-P versus AS+MQ 4 186 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.45]
7.2 DHA-P versus AL6 3 237 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.04, 0.58]
7.3 DHA-P versus AS+AQ 2 108 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.00, 0.73]
7.4 DHA-P versus AS+SP 1 77 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.15, 0.72]
7.5 AS+MQ versus AL6 2 56 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.40]
7.6 AS+MQ versus AS+AQ 1 34 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.7 AL6 versus AS+AQ 1 28 Risk Ratio (M-H, Random, 95% CI) 16.06 [1.03, 249.60]
7.8 AL6 versus AS+SP 1 72 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.67, 1.68]
Comparison 5. DHA-P versus alternative ACTs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrent parasitaemia - settings
described as low transmission
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Before day 28 4 239 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.02, 0.63]
1.2 After day 28 - without
primaquine
4 187 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.59, 1.09]
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1.3 During full follow-
up period (42 to 63 days) -
without primaquine
4 201 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.56, 1.02]
2 Recurrent parasitaemia - settings
described as high transmission
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Before day 28 3 334 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.08, 0.49]
2.2 After day 28 - with
primaquine
2 179 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.10, 0.46]
2.3 After day 28 - without
primaquine
1 66 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.14, 1.10]
2.4 During full follow-
up period (42 days) - with
primaquine
2 210 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.08, 0.32]
2.5 During full follow-up
period (42 days) - without
primaquine
1 108 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.24, 0.72]
A D D I T I O N A L T A B L E S
Table 1. Detailed search strategy
Search set Search terms used for all databases1
1 vivax
2 Arte*
3 Dihydroarte*
4 2 or 3
5 1 and 4
6 (search terms for RCTs)
7 5 and 6
8 Limit 7 to Human
1 Cochrane Infectious Disease Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in
The Cochrane Library; MEDLINE; EMBASE; and LILACS.
Table 2. Median parasite clearance times
Study ID Comparison Median parasite clearance time (range) P value
ACT CQ
Krudsood 2007 THA AL6 versus CQ 41.6 hrs 55.8 hrs < 0.01
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Table 2. Median parasite clearance times (Continued)
Poravuth 2010 ASIA AS-Py versus CQ 23.0 hrs (7.0 to 55.9) 32.0 hrs (7.5 to 63.9) < 0.0001
Table 3. Fever clearance times
Study ID Comparison Median fever clearance time (range) P value
ACT CQ
Krudsood 2007 THA AL6 versus CQ 21.8 hrs 25.3 hrs 0.12
Poravuth 2010 ASIA AS-Py versus CQ 15.9 hrs 23.8 hrs 0.0017
WH A T ’ S N E W
Last assessed as up-to-date: 28 March 2013.
Date Event Description
30 September 2013 New search has been performed We performed a new search in March 2013 and we
included two new trials. New authors joined the team
and one author stood down
30 September 2013 New citation required but conclusions have not
changed
We performed a new search and included two new
trials. There is no substantial change to the conclusions
H I S T O R Y
Protocol first published: Issue 4, 2010
Review first published: Issue 7, 2011
Date Event Description
3 August 2011 Amended We amended figures and tables to improve readability.
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C O N T R I B U T I O N S O F A U T H O R S
David Sinclair, Felicity Brand, and Piero Olliaro conceived and designed the protocol. For the original review David Sinclair, Felicity
Brand, and Nithya Gogtay extracted the data, and David Sinclair analysed the data and wrote the first draft with Nithya Gogtay. For
this update. Nithya Gogtay, Kannan Sridharan, and Urmila Thatte screened the search articles, extracted data, and analysed the data.
David Sinclair and Piero Olliaro assisted with revising subsequent drafts and preparing the final draft for publication.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Department for International Development (DFID), UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following adjustments:
The protocol stated: ’For the primary outcome ’Recurrence of P. vivax by day 14 or 28’ we will subgroup trials according to those which
also gave primaquine and those which did not’. In conducting the review we found that there were too few trials to make this subgroup
analysis informative.
The protocol stated: ’For the secondary outcome with prolonged follow-up ’Recurrence of P. vivax parasitaemia at 1 to 12 months’ we will
only include trials which also give the WHO recommended dose of primaquine to both treatment arms’.We chose to include the trials where
primaquine was not given as this is informative for settings where primaquine is not administered routinely due to either a high local
prevalence of G6PD or very high transmission intensity.
When analysing the data for’Recurrent parasitemias after day 28’ we excluded the participants who had experienced a recurrence before
day 28 from both the numerator and the denominator. This was not explicitly stated in the protocol. The reasoning for this change
was to prevent a drug which was superior in the first 28 days (more indicative of treatment of the blood stage) appearing superior at 42
days or longer (more indicative of an effect on relapse or re-infection) even if there was no difference during the second period.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Antimalarials [∗therapeutic use]; Artemisinins [∗therapeutic use]; Drug Combinations; Drug Resistance; Drug Therapy, Combination
[methods]; Ethanolamines [therapeutic use]; Fluorenes [therapeutic use]; Malaria, Vivax [∗drug therapy; prevention & control]; Par-
asitemia [∗drug therapy]; Primaquine [therapeutic use]; Pyrimethamine [therapeutic use]; Quinolines [therapeutic use]; Randomized
Controlled Trials as Topic; Secondary Prevention; Sulfadoxine [therapeutic use]
MeSH check words
Humans
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